Chiral indole compounds and uses thereof
Chiral indole compounds are developed to modulate AhR activity, addressing the lack of effective treatments for cancer and immune-related conditions by stimulating the immune system and inhibiting tumor growth.
Patent Information
- Application Number
- JP2021560842
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-13
- Filing Date
- 2020-04-15
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2040-04-15
AI Technical Summary
Current treatments for conditions mediated by the aryl hydrocarbon receptor (AhR) lack effective modulators that can selectively target and regulate its activity for therapeutic benefits in patients with cancer or immune stimulation.
Development of chiral indole compounds that modulate the activity of the human aryl hydrocarbon receptor (AhR), providing pharmaceutical compositions for treating conditions such as cancer and immune-related disorders by administering therapeutically effective amounts of these compounds.
The chiral indole compounds effectively stimulate the immune system, reduce IL-21 levels, and inhibit tumor growth in various cancer types, including hematological malignancies and solid tumors, while also offering potential treatments for immune dysregulation disorders.
Smart Images

Figure 0007595024000237 
Figure 0007595024000238 
Figure 0007595024000239
Abstract
Description
[Technical Field]
[0001] REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 834,140, filed April 15, 2019, and U.S. Provisional Application No. 62 / 861,123, filed June 13, 2019, the disclosures of which are incorporated herein by reference in their entireties.
[0002] FIELD OF THE INVENTION The present disclosure relates to chiral indole compounds and their use in treating patients in need of treatment, such as patients with cancer or patients in need of immune stimulation. [Background technology]
[0003] Background of the Invention The aryl hydrocarbon (Ah) receptor (AhR) is a ligand-inducible transcription factor and a member of the basic helix-loop-helix / Per-Arnt-Sim (bHLH / PAS) superfamily. Upon binding to its ligand, AhR mediates a range of biological processes, including cell division, apoptosis, cell differentiation, adipose differentiation, hypothalamic action, angiogenesis, immune system regulation, teratogenesis, tumorigenicity, tumor progression, chloracne, wasting, hormonal (e.g., estrogen and androgen) action, and expression of P450 family genes (Poland et al., Annu. Rev. Pharmacol. Toxicol. 22:517-554). (1982);Poellinger et al., Food Addit Contam. 17(4):261-6 (2000);Bock et al., Biochem. Pharmacol. 69(10):1403-1408 (2005);Stevens et al., Immunology 127(3):299-311 (2009);Puga (E. et al., Biochem Pharmacol. 69(2):199-207 (2005); Safe et al., Int J Oncol. 20(6):1123-8 (2002); Dietrich et al., Carcinogenesis 31(8):1319-1328 (2010); U.S. Patent No. 7,419,992). Ligand-bound receptors participate in biological processes through translocation from the cytoplasm to the nucleus, heterodimerization with another factor called the Ah receptor nuclear translocator, and binding of the heterodimer to Ah response elements of AhR-regulated genes, resulting in either increased or inhibited transcription of these genes.
[0004] The AhR can bind with different affinities to several groups of exogenous chemicals or artificial ligands, including polycyclic aromatic hydrocarbons, such as 3-methylcholanthrene (3-MC), and halogenated aromatic hydrocarbons, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Studies with these AhR artificial ligands have helped advance our understanding of the AhR system. Endogenous or physiological ligands for the AhR have the following structure: [ka] It has been identified as 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), having the formula: See, e.g., Song et al., PNAS USA 99(23):14694-9 (2002); and U.S. Patent No. 6,916,834. Summary of the Invention
[0005] Summary of the Invention The present disclosure provides indole compounds useful for modulating the activity of the human aryl hydrocarbon receptor (AhR), pharmaceutical compositions comprising one or more of these compounds, or the use of these compounds and compositions in the treatment of diseases and conditions in patients that may benefit from modulation of AhR activity.
[0006] Formula 2: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are completed with H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 is OR O , N(R N )2 or SR S and; R O is H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R Sis H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R1 and R 1a Let's get together =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (—O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, R2 may preferably be ═O, and R3 may preferably be —OR, where R is H or C1-C6 alkyl, or R1 and R 1a Let's get together, =CR b R c where R b and R care each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino, R2 may preferably be =O, and R3 may preferably be -OR, where R is H or C1-C6 alkyl, or R1 and R 1a Together =O, =NOR a or form =S, and R2 and R3 are preferably each independently -OR or -NR a R b where R and R a and R b are each independently H, C1-C6 alkyl, or C1-C6 acyl; R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; The compound has R2 / R3 / R 3a and optionally adjacent R groups can be joined to form a 3- to 12-membered ring. is provided herein.
[0007] Formula 2a: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 is OR O , N(R N )2 or SR S and; R O is H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R S is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (—O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, R2 may preferably be ═O, and R3 may preferably be —OR, where R is H or C1-C6 alkyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino, R2 may preferably be =O, and R3 may preferably be -OR, where R is H or C1-C6 alkyl, or R1 and R 1a Together, =O, =NOR a or form =S, and R2 and R3 are preferably each independently -OR or -NR a R b where R and R a and R b are each independently H, C1-C6 alkyl, or C1-C6 acyl; R1 and R 1aare each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; The compound has R2 / R3 / R 3a and optionally adjacent R groups can be joined together to form a 3- to 12-membered ring. Also provided herein are:
[0008] Formula 3: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1aare each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] Deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, and the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. Also provided herein are:
[0009] Formula 3a: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. is further provided herein.
[0010] Formula 3b: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where Rb and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b, -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. is further provided herein.
[0011] Formula 3c: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are equal to H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1aare each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. Also provided herein are:
[0012] Formula 4: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X is O (oxygen) or S (sulfur); Y is a bond, O (oxygen), S (sulfur) or [ka] and; Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 is OR O , N(R N )2 or SR S and; R Ois H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R S is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; wherein the compound is R2 / R3 / R 3a and optionally, adjacent R groups can be joined to form a 3- to 12-membered ring. Also provided herein are:
[0013] Formula 5: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X is O (oxygen) or S (sulfur); Y is a bond, O (oxygen), S (sulfur) or [ka] and; Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a, -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. is further provided herein.
[0014] Formula 6: [ka] or a pharmaceutically acceptable salt thereof (In the formula: Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 14 (n=0-2, R 14 is directly attached to S), where R 14is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; B1, B2, B3, B4, B5 and B6 are each independently C or N; R9 and R 10 The numbers of these together match the valences of B1, B2, B3, B4, B5 and B6, and R9 and R 10 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12represents hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and [ka] selected from the group consisting of where R 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino; R2 and R3 each independently represent -NR a R b (R a and R b are each independently H, C1-C6 alkyl or C1-C6 acyl), hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 13 (n=0-2, R 13 is directly attached to S), where R 13is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio, wherein the compound is selected from the group consisting of R or R 10 Partially enantiomerically pure; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. Also provided herein are:
[0015] In each of Formulas 2, 2a, 3, 3a, 3b, 3c, 4, 5, and 6, in some embodiments, each of R4, R5, R6, and R7 is hydrogen. In other embodiments, at least one of R4, R5, R6, and R7 can be F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. In still other embodiments, at least two of R4, R5, R6, and R7 can independently be F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. F, Cl, or Br can be at indole ring carbon 5, 6, or 7.
[0016] In each of formulas 2a, 3, 3a, 3b, 3c, 4, 5, and 6, in certain embodiments, R9 can be hydrogen. R2 can be acyl, cyano, hydroxyl-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, aryl, or heteroaryl. The aryl or heteroaryl can be substituted or unsubstituted. The substituted aryl or heteroaryl can be substituted with halo, amino, hydroxyl, or C1-C6 alkyl. The amino can be unsubstituted.
[0017] In each of formulas 2, 2a, and 4, in certain embodiments, R2 can be an ester.
[0018] In each of Formulas 2, 2a, and 4, in certain embodiments, R2 can be hydroxyl or amino, and R3 can be alkyl, aryl, nitro, or cyano. R9 can be hydrogen. The amino can be substituted or unsubstituted.
[0019] In some embodiments, the present invention provides a compound of formula 8a, 8b, 8c, or 8d: [ka] [ka] (In the formula: R4, R5, R6 and R7 are each independently selected from the group consisting of hydrogen and halo; R o is hydrogen, deuterium, alkyl, aryl, or acyl; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety or a pharmaceutically acceptable salt thereof.
[0020] In one embodiment, R o is H or alkyl. In another embodiment, R o is acyl, for example, substituted or unsubstituted C1-C6 acyl. The substituted or unsubstituted C1-C6 acyl can be a substituted C2, C3, C4, C5, or C6 acyl, optionally interrupted by O, S, or NR (wherein NR can be N-C1-C6 alkyl). The substituent can be a halo, carboxyl, amino, hydroxyl, alkoxy, or phosphate moiety. The amino moiety can be a dialkylamino moiety, for example, dimethylamino, morpholino, piperazinyl, or bipiperidinyl.
[0021] In one embodiment of a compound of structural formula 8a or 8b, at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. In another embodiment, at least two of R4, R5, R6, and R7 are F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen.
[0022] In one embodiment, R5 is F and R4, R6 and R7 are hydrogen. In another embodiment, R6 is F and R4, R5 and R7 are hydrogen. In yet another embodiment, R7 is F and R4, R5 and R6 are hydrogen.
[0023] In one embodiment, R5 is Cl and R4, R6 and R7 are hydrogen. In another embodiment, R6 is Cl and R4, R5 and R7 are hydrogen. In yet another embodiment, R7 is Cl and R4, R5 and R6 are hydrogen.
[0024] In one embodiment, R5 and R6 are F and R4 and R7 are hydrogen. In another embodiment, R5 and R7 are F and R4 and R6 are hydrogen. In yet another embodiment, R6 and R7 are F and R4 and R5 are hydrogen.
[0025] In one embodiment, R5 and R6 are Cl and R4 and R7 are hydrogen. In another embodiment, R5 and R7 are Cl and R4 and R6 are hydrogen. In yet another embodiment, R6 and R7 are Cl and R4 and R5 are hydrogen.
[0026] In some embodiments, each of R4, R5, R6 and R7 is hydrogen.
[0027] In some embodiments, R N can be a phosphate moiety. The phosphate moiety has the structure [ka] where n can be 0, 1, 2, 3, 4, 5, or 6; R x can be H or C1-C6 alkyl, R y can be H or C1-C6 alkyl, or R x and R y together form a C3-C8 cycloalkyl, and Q1 + and Q2 + may each independently be a monocation or together be a dication, or Q1 + Or Q2 + One of the groups is C1-C6 alkyl, benzyl, allyl, or -(CR2R3-O)-R 23 and R2, R3 and R 23 may independently be H or C1-C6 alkyl). In certain embodiments, the phosphate moiety may be a phosphorus-containing aralkyl group, such as a benzyl group.
[0028] In some embodiments, n can be 0 or 1.
[0029] In certain circumstances, Q1 + and Q2 + may each independently be an alkali metal.
[0030] In certain circumstances, Q1 + and Q2 + may each independently be selected from the group consisting of lithium, sodium, potassium, ammonium, alkylammonium, and phosphonium.
[0031] In certain circumstances, Q1 + and Q2 + together may be selected from the group consisting of alkaline earth metal salts.
[0032] In certain circumstances, Q1 + and Q2 + may each independently be selected from the group consisting of zinc, calcium, and magnesium.
[0033] In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-164) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-165) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-186) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-092) or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-192) or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-193) or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-196) or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-197), or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-198), or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-199), or an enantiomer or pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides a compound selected from the compounds in Table 1 (ARI-205), or an enantiomer or pharmaceutically acceptable salt thereof.
[0034] The present disclosure also provides pharmaceutical compositions comprising a compound described herein and a pharmaceutically acceptable carrier.
[0035] The present disclosure provides a method for stimulating the immune system in a patient in need of immune system stimulation, comprising administering a therapeutically effective amount of a compound or pharmaceutical composition described herein to the patient. In some embodiments, after the administration step, the patient has an increased number of cells selected from the group consisting of leukocytes, macrophages, neutrophils, lymphocytes (e.g., B lymphocytes and / or T lymphocytes), natural killer (NK) cells, dendritic cells, and platelets, or an increased level of cytokines indicative of a stimulated immune system. In some embodiments, the compound reduces IL-21 levels in the patient. In some embodiments, the patient has cancer.
[0036] The present disclosure also provides a method for treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of a compound described herein. In some embodiments, the cancer is a hematological malignancy (e.g., lymphoma, leukemia, or myeloma) or a solid tumor. In some embodiments, the cancer may be selected from the group consisting of diffuse large B-cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, prolymphocytic leukemia, acute lymphocytic leukemia, Waldenstrom's macroglobulinemia (WM), follicular lymphoma, mantle cell lymphoma (MCL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, prostate cancer, ovarian cancer, fallopian tube cancer, cervical cancer, breast cancer, lung cancer (e.g., non-small cell lung cancer), skin cancer (e.g., melanoma), colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, soft tissue cancer, glioma, and head and neck cancer. In some embodiments, the method further comprises administering to the patient another cancer therapeutic agent, for example, an immune checkpoint inhibitor (e.g., a PD-1, PD-L1, and / or PD-L2 inhibitor). In some embodiments, the method further comprises administering one or more maintenance doses of the compound while the patient is in remission.
[0037] In the methods of treatment described herein, also provided herein are compounds or pharmaceutical compositions described herein for use in modulating or stimulating the immune system (e.g., in patients with immune dysregulation or an autoimmune disease such as multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, or psoriasis) or treating cancer in a patient in need of such treatment.
[0038] The present disclosure further provides for the use of the compounds described herein in the methods of treatment described herein, for the manufacture of a medicament for modulating or stimulating the immune system or treating cancer in a patient in need thereof.
[0039] The present disclosure also provides articles of manufacture, such as kits, that include the compounds described herein.
[0040] The present disclosure also provides a compound of formula 9: [ka] (In the formula: Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; Ro is hydrogen, deuterium, alkyl, aryl, or acyl; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof, comprising: (i) contacting a compound of formula 10 with (S)-2-methylpropane-2-sulfinamide in the presence of a catalyst to obtain a compound of formula 11; [ka] (ii) contacting a compound of formula 11 with one or more alkylating agents to provide a compound of formula 12; [ka] (iii) contacting a compound of formula 12 with a compound of formula 13 in the presence of an organolithium base to obtain a compound of formula 14; [ka] (iv) subjecting the compound of formula 14 to acid-base hydrolysis to obtain the compound of formula 9 The present invention provides a method comprising:
[0041] In some embodiments, R4, R5, R6, R7, R8, R9 and R N Each of is hydrogen.
[0042] In some embodiments, at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen.
[0043] In some embodiments, R o , R3 and R 3aare independently H or alkyl.
[0044] In some embodiments, at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N.
[0045] In some embodiments, the compound of formula 9 is NHR o / R3 / R 3a It is enantiomerically pure at the carbon substituted with .
[0046] In some embodiments, R and R 3a taken together form a 3- to 12-membered ring, including a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
[0047] In some embodiments, the catalyst is a transition metal alkoxide.
[0048] In certain embodiments, the transition metal alkoxide is a titanium alkoxide.
[0049] The present disclosure also provides a process for producing a compound of formula (I) comprising contacting thiazole-4-carbaldehyde with (S)-2-methylpropane-2-sulfinamide in the presence of titanium isopropoxide to obtain (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide; contacting (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide with ethylmagnesium bromide to obtain (S)-2-methyl-N-(1-(thiazol-4-yl)propyl)propane-2-sulfinamide; contacting (S)-2-methyl-N-(1-(thiazol-4-yl)propyl)propane-2-sulfinamide with tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate in the presence of an organolithium compound base to obtain (S)—N-((S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl)-2-methylpropane-2-sulfinamide; and subjecting (S)—N—((S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl)-2-methylpropane-2-sulfinamide to acid-base hydrolysis to obtain (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone. The present invention provides a method for making (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone, comprising: [Brief explanation of the drawings]
[0050] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] FIG. 1 shows the synthetic scheme for ARI-164 and ARI-165 according to Example 1. [Figure 2] FIG. 2 shows the synthetic scheme for ARI-164 and ARI-165 according to Example 2. [Figure 3] FIG. 3 shows the synthetic scheme for ARI-092 and ARI-094 according to Example 3. [Figure 4] FIG. 4 shows a chiral synthesis scheme for ARI-164 and ARI-165 according to Example 4. [Figure 5] FIG. 5 shows the synthesis scheme for PTC17341-138 and PTC17341-139 according to Example 5. [Figure 6] FIG. 6 shows the synthesis scheme for PTC17341-133A and PTC17341-133B according to Example 6. [Figure 7-1] Figure 7A shows a synthetic scheme for compounds ARI-196, ARI-197, ARI-198, ARI-199, and ARI-205 according to Examples 9 to 13. Figure 7B shows a synthetic scheme for compound ARI-192 according to Example 14. [Figure 7-2] FIG. 7C shows a synthetic scheme for compound ARI-193 according to Example 15. [Figure 8] FIG. 8 shows a synthetic scheme for compound ARI-075 according to Example 16. [Figure 9] FIG. 9 shows a synthetic scheme for compound ARI-209 according to Example 18. [Figure 10] FIG. 10 shows a synthetic scheme for compound ARI-215 according to Example 20. [Figure 11] FIG. 11 shows a synthetic scheme for compound ARI-221 according to Example 22. [Figure 12] FIG. 12 shows a synthetic scheme for compound ARI-225 according to Example 23. [Figure 13] FIG. 13 shows a synthetic scheme for compound ARI-226 according to Example 24. [Figure 14] FIG. 14 shows a synthetic scheme for compound ARI-217 according to Example 25. [Figure 15-1] FIG. 15A shows a synthetic scheme for compound ARI-186 according to Example 26. [Figure 15-2] 15B shows a synthetic scheme for compound ARI-232 according to Example 27. FIG. 15C shows a synthetic scheme for compound ARI-233 according to Example 28. [Figure 15-3] 15D shows a synthetic scheme for compound ARI-234 according to Example 29. FIG. 15E shows a synthetic scheme for compound ARI-235 according to Example 30. [Figure 15-4] FIG. 15F shows a synthetic scheme for compound ARI-236 according to Example 31. [Figure 16-1]Figure 16A is a plot showing the mean plasma concentration-time profile of ARI-186 after IV administration of 5 mg / kg in Balb / C mice, and Figure 16B is a plot showing the mean plasma concentration-time profile of ARI-186 after PO administration of 10 mg / kg in Balb / C mice. [Figure 16-2] Figure 16C is a plot showing the mean plasma concentration-time profile of ARI-186 after PO administration of 40 mg / kg in Balb / C mice. Figure 16D is a plot showing the mean plasma concentration-time profile of ARI-186 after IP administration of 40 mg / kg in Balb / C mice. [Figure 17] 17A and 17B are plots showing the individual plasma concentration-time profiles of ARI-186 following PO administration of 10 mg / kg in SD rats on days 1 and 5, respectively. [Figure 18] 18A and 18B are plots showing the individual plasma concentration-time profiles of ARI-224 following PO administration of 10 mg / kg in SD rats on days 1 and 5, respectively. [Figure 19] 19A and B are plots showing the individual plasma concentration-time profiles of ARI-226 following PO administration of 10 mg / kg in SD rats on days 1 and 5, respectively. [Figure 20-1] 20A and 20B are plots comparing the tumor inhibitory activity of ARI-143, ARI-164, and ARI-165 in the EMT-6 syngeneic mouse tumor model. [Figure 20-2] FIG. 20C is a plot comparing the tumor inhibitory activity of ARI-164 (80 mpk) and ARI-186 (20 mpk) in the Pan02 syngeneic mouse tumor model. [Figure 21-1] Figure 21A is a plot comparing the tumor inhibitory activity of ARI-164, anti-PD-1, and their combination in 4T-1, A20, EMT-6, Pan02, H22, LL / 2, and MC38 syngeneic mouse tumor models. [Figure 21-2]Figures 21B-C are plots comparing the tumor inhibitory activity of ARI-164, anti-PD-1, and their combination in 4T-1, A20, EMT-6, Pan02, H22, LL / 2, and MC38 syngeneic mouse tumor models. [Figure 21-3] Figures 21D-E are plots comparing the tumor inhibitory activity of ARI-164, anti-PD-1, and their combination in 4T-1, A20, EMT-6, Pan02, H22, LL / 2, and MC38 syngeneic mouse tumor models. [Figure 21-4] Figures 21F-G are plots comparing the tumor inhibitory activity of ARI-164, anti-PD-1, and their combination in 4T-1, A20, EMT-6, Pan02, H22, LL / 2, and MC38 syngeneic mouse tumor models. DETAILED DESCRIPTION OF THE INVENTION
[0051] Detailed Description of the Invention All technical and scientific terms used herein are the same as commonly used by one of ordinary skill in the art to which this invention belongs, unless specifically defined otherwise.
[0052] The moieties described below can be substituted or unsubstituted. "Substituted" refers to the replacement of a hydrogen atom of a molecule or R group with one or more additional R groups, such as deuterium, halogen, alkyl, haloalkyl, alkenyl, alkoxy, alkoxyalkyl, alkylthio, trifluoromethyl, acyloxy, hydroxy, hydroxyalkyl, mercapto, carboxy, cyano, acyl, aryloxy, aryl, arylalkyl, heteroaryl, amino, aminoalkyl, alkylamino, dialkylamino, morpholino, piperidino, pyrrolidin-1-yl, piperazin-1-yl, nitro, phosphine, phosphinate, phosphonate, sulfate, =0, =S, or other R groups. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group. The combinations of substituents contemplated herein are preferably stable (e.g., substantially unchanged for more than one week when stored at a temperature of 40°C or less in the absence of humidity or other chemically reactive conditions) or result in the formation of a chemically feasible compound.
[0053] "Hydroxy", "thiol", "cyano", "nitro" and "formyl" refer to -OH, -SH, -CN, -NO2 and -CHO, respectively.
[0054] "Acyloxy" refers to the RC(=O)O- radical, where R is alkyl, cycloalkyl, aryl, heteroalkyl, heteroaryl, or heterocycloalkyl, as described herein. In some embodiments, acyloxy is a C1-C4 acyloxy radical, which refers to the total number of chain or ring atoms and acyl carbonyl carbon of the alkyl, cycloalkyl, aryl, heteroalkyl, heteroaryl, or heterocycloalkyl portion of the acyloxy group, i.e., other ring or chain atoms and carbonyl. When the R radical is heteroaryl or heterocycloalkyl, the heterocycle or chain atoms contribute to the total number of chain or ring atoms.
[0055] "Alkyl" refers to a group of 1 to 18, 1 to 16, 1 to 12, 1 to 10, preferably 1 to 8, more preferably 1 to 6 unsubstituted or substituted hydrogen saturated carbons linked in a straight, branched, or cyclic fashion, including combinations of straight, branched, and cyclic connectivities. Non-limiting examples include methyl, ethyl, propyl, isopropyl, butyl, and pentyl.
[0056] "Cycloalkyl" refers to a monocyclic or polycyclic non-aromatic radical that contains carbon and hydrogen and can be saturated or partially unsaturated. A cycloalkyl group is a group having 3 to 10 ring atoms (e.g., C3-C4). 10 cycloalkyl). Whenever cycloalkyl appears herein, a numerical range such as "3 to 10" refers to each integer within the specified range; for example, "3 to 10 carbon atoms" means that the cycloalkyl group can consist of 3 carbon ring atoms, 4 carbon ring atoms, 5 carbon ring atoms, etc., up to and including 10 carbon ring atoms. In some embodiments, cycloalkyl is a C3-C8 cycloalkyl radical. In some embodiments, cycloalkyl is a C3-C5 cycloalkyl radical. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloseptyl, cyclooctyl, cyclononyl, cyclodecyl, and norbornyl. The term "cycloalkyl" also refers to a helical ring system in which the cycloalkyl rings share one carbon atom.
[0057] "Heterocycloalkyl" refers to a 3- to 18-membered non-aromatic ring (e.g., C3-C6) containing 2 to 12 ring carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. 18 Heterocycloalkyl refers to a C5-C6 heterocycloalkyl (heterocycloalkyl) radical. Whenever heterocycloalkyl appears herein, a numerical range such as "3 to 18" refers to each integer within the specified range; for example, "3 to 18 ring atoms" means that the heterocycloalkyl group can consist of 3 ring atoms, 4 ring atoms, etc., up to and including 18 ring atoms. In some embodiments, heterocycloalkyl refers to a C5-C6 heterocycloalkyl.10 In some embodiments, heterocycloalkyl is C-C 10 In some embodiments, heterocycloalkyl is C-C 10 Heterocycloalkyl. Heterocycloalkyl radicals can be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which can include fused or bridged ring systems. The heteroatoms in the heterocycloalkyl radical can be optionally oxidized. If present, one or more nitrogen atoms can be optionally quaternized. The heterocycloalkyl radical can be partially or fully saturated. The heterocycloalkyl can be attached to the rest of the molecule through any atom of the ring(s). Examples of such heterocycloalkyl radicals include, but are not limited to, 6,7-dihydro-5H-cyclopenta[b]pyridine, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. In some embodiments, the heterocycloalkyl group is aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, indolinyl, tetrahydroquinolyl, tetrahydroisoquinoline, and benzoxazinyl, preferably dihydrooxazolyl and tetrahydrofuranyl.
[0058] "Halo" refers to any of the halogen atoms fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). A particular example of such a halo group is fluorine.
[0059] "Haloalkyl" refers to an alkyl substituted with one or more halo.
[0060] "Alkenyl" refers to an unsubstituted or substituted hydrocarbon radical containing 2 to 18, 2 to 16, 2 to 12, 2 to 10, for example, 2 to 8 (e.g., 2 to 6) carbons that is linear, branched, cyclic, or a combination thereof, and has at least one carbon-carbon double bond.
[0061] "Haloalkenyl" refers to an alkenyl substituted with one or more halo.
[0062] "Alkynyl" refers to an unsubstituted or substituted hydrocarbon radical containing 2 to 18, 2 to 16, 2 to 12, 2 to 10, for example, 2 to 8 (for example, 2 to 6) carbons which may be linear, branched, cyclic, or a combination thereof, and which has at least one carbon-carbon triple bond.
[0063] "Haloalkynyl" refers to an alkynyl substituted with one or more halo.
[0064] "Amino-protecting group" refers to a group intended to protect an amino group against undesired reactions during synthetic procedures and which can be subsequently removed to yield an amine. Commonly used amino-protecting groups are disclosed in Protective Groups in Organic Synthesis, Greene, TW; Wuts, PGM, John Wiley & Sons, New York, NY, (3rd edition, 1999).Amino-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl and p-toluenesulfonyl; alkoxy- or aryloxy-carbonyl groups (which form urethanes with the protected amine), such as benzyloxycarbonyl (Cbz), p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro -4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl (Boc), diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl (Alloc), 2,2,2- Examples of amino-protecting groups include trichloroethoxycarbonyl, 2-trimethylsilylethyloxycarbonyl (Teoc), phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl (Fmoc), cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, phenylthiocarbonyl, and the like; aralkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl, and the like; and silyl groups such as trimethylsilyl, etc. Amino-protecting groups also include cyclic amino-protecting groups that incorporate the amino nitrogen into a heterocycle, such as phthaloyl and dithiosuccinimidyl.Typically, amino protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, Alloc, Teoc, benzyl, Fmoc, Boc and Cbz.
[0065] "Amino" refers to unsubstituted and substituted amino groups, such as primary amines, secondary amines, tertiary amines, and quaternary amines. Specifically, "amino" refers to -NR a R b where R a and R b are both directly attached to N and independently represent hydrogen, deuterium, halo, hydroxy, cyano, formyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, a nitrogen protecting group, -(CO)-alkyl, -(CO)-O-alkyl, or -S(O) n R c (n=0-2, R c is directly attached to S), where R c are independently selected from hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, or halothiocarbonylthio.
[0066] "Aryl" refers to C6-C 14 It refers to an aromatic hydrocarbon. For example, aryl can be phenyl, naphthyl, or fluorenyl.
[0067] "Heteroaryl" refers to a C-C heteroaryl having one or more heteroatoms, such as N, O, or S. 14Heteroaryl refers to an aromatic hydrocarbon. Heteroaryl can be substituted or unsubstituted. Examples of heteroaryl include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, benzo[b][l,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzofurazanyl, Benzothiazolyl, benzothienyl, benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[l,2-c]pyridazinyl, dibenzofuranyl, dibenzyl Zothiophenyl, furanyl, furazanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5 ,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5 ]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (i.e., thienyl). In some embodiments, heteroaryl is dithiazinyl, furyl, imidazoyl, indolyl, isoquinolinyl, isoxazolyl, oxadiazolyl (e.g., (1,3,4)-oxadiazolyl or (1,2,4)-oxadiazolyl), oxazolyl, pyrazinyl, pyrazolyl, pyrazyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrimidyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienyl, triazinyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, 5-amino-1,2,4-oxadiazolyl, 5-amino-1,3,4-oxadiazolyl, 5-amino-1,3,4-oxadiazolyl, 3-methyl-1,2,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 5-(trifluoromethyl)-1,2,4-oxadiazolyl, 5-(methylamino)-1,2,4-oxadiazolyl, 5-(aminomethyl)-1,2,4-oxadiazolyl, 5-(aminomethyl)-1,3,4-oxadiazolyl, 5-amino-4-cyanooxazolyl, 5,6-dichloro-1H-indolyl, 5,6-difluoro-1H-indolyl, 5-chloro-1H-indolyl, 5,It may be 6-dibromo-1H-indolyl, 5-fluoro-1H-indolyl, 5-methoxy-1H-indolyl, 7-fluoro-1H-indolyl, 6-cyano-1H-indolyl, 5-cyano-1H-indolyl, 4-fluoro-1H-indolyl, 5,6-difluoro-1H-indolyl, 6-fluoro-1H-indolyl, or 5,7-difluoro-1H-indolyl.
[0068] Substituents on the heteroaryl group can be alkyl (e.g., C1-C6 alkyl), amino, cyano, halo (e.g., fluoro, bromo, and chloro), alkylamino (e.g., C1-C6 alkylamino), methyleneamino, nitro, or hydroxyl. The heteroaryl group can have 2, 3, or 4 substituents.
[0069] "Carbocycle" is C6-C 14 For example, aryl can be phenyl, naphthyl, or fluorenyl.
[0070] A "heterocycle" is a C-C ring with one or more heteroatoms such as N, O, or S. 14 It refers to cyclic hydrocarbons.
[0071] "Alkoxy" refers to an alkyl attached to an oxygen atom (-O-alkyl).
[0072] "Haloalkoxy" refers to a haloalkyl attached to an oxygen atom (-O-haloalkyl).
[0073] "Thioalkoxy" refers to an alkyl attached to a sulfur atom (-S-alkyl).
[0074] "Halothioalkoxy" refers to a haloalkyl attached to a sulfur atom (-S-haloalkyl).
[0075] "Carbonyl" refers to -(CO)-, where (CO) indicates that the oxygen is attached to the carbon with a double bond.
[0076] "Alkanoyl" or "acyl" refers to an alkyl linked to a carbonyl group [-(CO)-alkyl].
[0077] "Haloalkanoyl" or "haloacyl" refers to a haloalkyl attached to a carbonyl group [-(CO)-haloalkyl].
[0078] "Thiocarbonyl" refers to -(CS)-, where (CS) indicates that the sulfur is attached to the carbon with a double bond.
[0079] "Thioalkanoyl (or thioacyl)" refers to an alkyl attached to a thiocarbonyl group [-(CS)-alkyl].
[0080] "Halothioalkanoyl" or "halothioacyl" refers to a haloalkyl [-(CS)-haloalkyl] attached to a thiocarbonyl group.
[0081] "Carbonyloxy" refers to an alkanoyl (or acyl) group [-O-(CO)-alkyl] attached to an oxygen atom.
[0082] "Halocarbonyloxy" refers to a haloalkanoyl (or haloacyl) group attached to an oxygen atom [-O-(CO)-haloalkyl].
[0083] "Carbonylthio" refers to an alkanoyl (or acyl) group attached to a sulfur atom [-S-(CO)-alkyl].
[0084] "Halocarbonylthio" refers to a haloalkanoyl (or haloacyl) group attached to a sulfur atom [-S-(CO)-haloalkyl].
[0085] "Thiocarbonyloxy" refers to a thioalkanoyl (or thioacyl) group [-O-(CS)-alkyl] attached to an oxygen atom.
[0086] "Halothiocarbonyloxy" refers to a halothioalkanoyl (or halothioacyl) [-O-(CS)-haloalkyl] attached to an oxygen atom.
[0087] "Thiocarbonylthio" refers to a thioalkanoyl (or thioacyl) [-S-(CS)-alkyl] attached to a sulfur atom.
[0088] "Halothiocarbonylthio" refers to a halothioalkanoyl (or halothioacyl) [-S-(CS)-haloalkyl] attached to a sulfur atom.
[0089] Indole compounds One aspect of the present disclosure relates to indole compounds that can modulate human aryl hydrocarbon receptor (AhR).These compounds specifically bind to AhR.Without wishing to be bound by theory, it is believed that the AhR that is bound by one of the present compounds is agonized in terms of the immunostimulatory activity of the receptor.
[0090] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of Formula 2: [ka] (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 is OR O , N(R N )2 or SR S and; R O is H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R S is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R1 and R 1a Let's get together =NR b where R bis H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (—O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, R2 may preferably be ═O, and R3 may preferably be —OR, where R is H or C1-C6 alkyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino, R2 may preferably be =O, and R3 may preferably be -OR, where R is H or C1-C6 alkyl, or R1 and R 1a Together =O, =NOR a or form =S, and R2 and R3 are preferably each independently -OR or -NR a R b where R and R a and R b are each independently H, C1-C6 alkyl, or C1-C6 acyl; R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; The compound has R2 / R3 / R 3a and optionally adjacent R groups can be joined to form a 3- to 12-membered ring. It has.
[0091] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of formula 2a: [ka] (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 is OR O , N(R N )2 or SR S and; R O is H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R Sis H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (—O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, R2 may preferably be ═O, and R3 may preferably be —OR, where R is H or C1-C6 alkyl, or R1 and R 1a Let's get together, =CR b R c where R b and R care each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino, R2 may preferably be =O, and R3 may preferably be -OR, where R is H or C1-C6 alkyl, or R1 and R 1a together, =O, =NOR a or form =S, and R2 and R3 are preferably each independently -OR or -NR a R b where R and R a and R b are each independently H, C1-C6 alkyl, or C1-C6 acyl; R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; The compound has R2 / R3 / R 3a and optionally adjacent R groups can be joined together to form a 3- to 12-membered ring. It has.
[0092] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of Formula 3: [ka] (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and Rc are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b, -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] Deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, and the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0093] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of Formula 3a: [ka] (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0094] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of Formula 3b: [ka] (In the formula: X is either O (oxygen) or S (sulfur); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and Rc are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b, -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0095] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has the structure of formula 3c: [ka] (In the formula: X1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and at least one of X1, X2, X3, and X4 is N, and each of X1, X2, X3, and X4 is optionally selected to form a heteroaromatic ring, wherein the bonds between X1 and the adjacent carbon, between X2 and the adjacent carbon, between X1 and X4, between X2 and X3, and between X3 and X4 can be single or double bonds, and the valences of X1, X2, X3, and X4 are equal to H or C1-C6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1aare each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0096] In yet another embodiment, the compound or a pharmaceutically acceptable salt thereof has structural formula 4: [ka] (In the formula: X is O (oxygen) or S (sulfur); Y is a bond, O (oxygen), S (sulfur) or [ka] and; Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R2 is OR O , N(R N )2 or SR S and; R Ois H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R S is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; wherein the compound is R2 / R3 / R 3a and optionally, adjacent R groups can be joined to form a 3- to 12-membered ring. It has.
[0097] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has structural formula 5: [ka] (In the formula: X is O (oxygen) or S (sulfur); Y is a bond, O (oxygen), S (sulfur) or [ka] and; Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R2 and R9 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino, wherein the compound is enantiomerically pure in the R2 or R9 moiety; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0098] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has structural formula 6: [ka] (In the formula: Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R1 and R 1a together, =NR b where R b is H, C1-C6 alkyl, hydroxy, C1-C6 alkoxy (-O-alkyl), C1-C6 acyloxy, amino or C1-C6 acyl, or R1 and R 1a Let's get together, =CR b R c where R b and R c are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN) or amino; R1 and R 1a Together, =O, =NOR a Or form =S, where R a is H, C1-C6 alkyl or C1-C6 acyl, or R1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 14 (n=0-2, R 14 is directly attached to S), where R 14is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R4, R5, R6, R7, and R8 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; B1, B2, B3, B4, B5 and B6 are each independently C or N; R9 and R 10 The numbers of these together match the valences of B1, B2, B3, B4, B5 and B6, and R9 and R 10 are each independently hydrogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, alkyl, -NR 2a C(O)OR 2b , -NR 2a C(O)R 2b , -(C0-C6 alkyl)-CONHSO2R 2a , -(C0-C6 alkyl)-CONHSO2NR 2a R 2b , -(C0-C6 alkyl)-SONHCOR 2a , -(C0-C6 alkyl)-SO2NHR 2a , -(C0-C6 alkyl)-CONR 2a OR 2b , [ka] , deuterium, halo, amino, hydroxy, cyano, formyl, nitro, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12represents hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and [ka] selected from the group consisting of where R 2a and R 2b are each independently H, C1-C6 alkyl, alkoxy (-O-alkyl), hydroxy, thioalkoxy (-S-alkyl), cyano (-CN), or amino; R2 and R3 each independently represent -NR a R b (R a and R b are each independently H, C1-C6 alkyl or C1-C6 acyl), hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 13 (n=0-2, R 13 is directly attached to S), where R 13is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio, wherein the compound is selected from the group consisting of R or R 10 Partially enantiomerically pure; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. It has.
[0099] In each of Formulas 2, 2a, 3, 3a, 3b, 3c, 4, 5, and 6, in some embodiments, R4, R5, R6, and R7 are each hydrogen. In other embodiments, at least one of R4, R5, R6, and R7 can be F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. In still other embodiments, at least two of R4, R5, R6, and R7 can independently be F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. F, Cl, or Br can be at indole ring carbon 5, 6, or 7.
[0100] In each of formulas 2a, 3, 3a, 3b, 3c, 4, 5, and 6, in certain embodiments, R9 can be hydrogen. R2 can be acyl, cyano, hydroxyl-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, aryl, or heteroaryl. The aryl or heteroaryl can be substituted or unsubstituted. The substituted aryl or heteroaryl can be substituted with halo, amino, hydroxyl, or C1-C6 alkyl. The amino can be unsubstituted.
[0101] In each of Formulas 2, 2a, and 4, in certain embodiments, R2 can be an ester. In each of Formulas 2, 2a, and 4, in certain embodiments, R2 can be hydroxyl or amino, and R3 can be alkyl, aryl, nitro, or cyano. R9 can be hydrogen. The amino can be substituted or unsubstituted.
[0102] In some embodiments, the compound or a pharmaceutically acceptable salt thereof has structural formula 8a, 8b, 8c, or 8d: [ka] [ka] wherein R4, R5, R6, and R7 are each independently selected from the group consisting of hydrogen and halo; R o is hydrogen, deuterium, alkyl, aryl, or acyl; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety It has.
[0103] In one embodiment, R o is H or alkyl. In another embodiment, R o is acyl, for example, substituted or unsubstituted C1-C6 acyl. The substituted or unsubstituted C1-C6 acyl can be a substituted C2, C3, C4, C5, or C6 acyl, optionally interrupted by O, S, or NR (wherein NR can be N-C1-C6 alkyl). The substituent can be a halo, carboxyl, amino, hydroxyl, alkoxy, or phosphate moiety. The amino moiety can be a dialkylamino moiety, for example, dimethylamino, morpholino, methylpiperazinyl, piperazinyl, or bipiperidinyl.
[0104] In one embodiment of a compound of structural formula 8a or 8b, at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen. In another embodiment, at least two of R4, R5, R6, and R7 are F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen.
[0105] In one embodiment, R5 is F and R4, R6 and R7 are hydrogen. In another embodiment, R6 is F and R4, R5 and R7 are hydrogen. In yet another embodiment, R7 is F and R4, R5 and R6 are hydrogen.
[0106] In one embodiment, R5 is Cl and R4, R6 and R7 are hydrogen. In another embodiment, R6 is Cl and R4, R5 and R7 are hydrogen. In yet another embodiment, R7 is Cl and R4, R5 and R6 are hydrogen.
[0107] In one embodiment, R5 and R6 are F and R4 and R7 are hydrogen. In another embodiment, R5 and R7 are F and R4 and R6 are hydrogen. In yet another embodiment, R6 and R7 are F and R4 and R5 are hydrogen.
[0108] In one embodiment, R5 and R6 are Cl and R4 and R7 are hydrogen. In another embodiment, R5 and R7 are Cl and R4 and R6 are hydrogen. In yet another embodiment, R6 and R7 are Cl and R4 and R5 are hydrogen.
[0109] In some embodiments, each of R4, R5, R6 and R7 is hydrogen.
[0110] In some embodiments, R N can be a phosphate moiety. The phosphate moiety has the structure [ka] where n can be 0, 1, 2, 3, 4, 5, or 6; R x can be H or C1-C6 alkyl, R y can be H or C1-C6 alkyl, or together, R x and R y forms a C3-C8 cycloalkyl, and Q1 + and Q2 + may each independently be a monocation, or together may be a dication, or Q1 + or Q2 + one of which is C1-C6 alkyl, benzyl, allyl or -(CR2R3-O)-R 23 and R2, R3 and R 23 each of which may independently be H or C1-C6 alkyl.
[0111] In some embodiments, n can be 0 or 1.
[0112] In certain circumstances, Q1 + and Q2 + may each independently be an alkali metal.
[0113] In certain circumstances, Q1 + and Q2 + may each independently be selected from the group consisting of lithium, sodium, potassium, ammonium, alkylammonium, and phosphonium.
[0114] In certain circumstances, Q1 + and Q2 + together may be selected from the group consisting of alkaline earth metal salts.
[0115] In certain circumstances, Q1 + and Q2 + may each independently be selected from the group consisting of zinc, calcium, and magnesium.
[0116] Exemplary indole compounds are shown in Table 1 below.
Table 1-1
Table 1-2
Table 1-3
Table 1-4
Table 1-5
Table 1-6
Table 1-7
Table 1-8
Table 1-9
Table 1-10
Table 1-11
Table 1-12
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
[0117] Single stereochemical isomers, enantiomers, diastereomers, and pharmaceutically acceptable salts of the above exemplified compounds are also within the scope of this disclosure. Where appropriate, pharmaceutically acceptable salts may be derived, for example, from suitable inorganic and organic acids and bases.
[0118] The compounds described herein may be isolated as pharmaceutically pure compounds. The compounds may be isolated as oils, crystalline solids, or amorphous solids. 3a When the compound is enantiomerically pure around the carbon substituted with R2 / R3 / R, the compound may be in at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 99.5% enantiomeric excess (ee). 3aThe enantiomeric configuration at the carbon substituted with may be the (R) configuration. Alternatively, R / R / R 3a The enantiomeric configuration at the carbon substituted with R2 / R3 / R can be the (S) configuration. 3a The enantiomeric configuration at the carbon substituted with R / R / R may be the (+) configuration. 3a The enantiomeric configuration at the carbon substituted with may be the (-) configuration.
[0119] Where appropriate, acid addition salts may be prepared by reacting the purified compound, if possible in its free base form, with a suitable organic or inorganic acid and isolating the salt formed. Examples of pharmaceutically acceptable acid addition salts include, but are not limited to, salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid.
[0120] Where appropriate, base addition salts can be prepared by reacting the purified compound in its acid form with a suitable organic or inorganic base and isolating the salt formed. Such salts include, but are not limited to, alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium, and N + (C 1-4 Examples include salts of alkyl)4.
[0121] Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, and 2-hydroxy-ethanesulfonate. These include phonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate salts.
[0122] In some embodiments, the compound may be selected from ARI-164 or ARI-165 or a pharmaceutically acceptable salt thereof.
[0123] The activity of indole compounds in stimulating AhR can be measured, for example, by the EROD assay described below. The EROD assay can be performed, for example, using human or mouse liver cell lines. The indole compounds of the present disclosure have an EC of about 100 nM or less (e.g., 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 9 nM or less, 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, or 0.1 nM or less) in the human or mouse EROD assay. 50 may have:
[0124] The antagonistic effect of indole compounds on AhR immunostimulatory activity was investigated using CD4 +In such assays, the indole compounds of the present disclosure have an IC50 of about 500 nM or less (e.g., 400 nM or less, 300 nM or less, 200 nM or less, 100 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 1 nM or less, or 0.1 nM or less). 50 may have:
[0125] The PK profiles of the indole compounds of the present invention are illustrated in the Examples below. The compounds have a T of 0.05 to 2 hours. max , 300 to 50,000 ng / mL C max , T of 0.5 to 5 hours 1 / 2 or may have an AUC of 1,000 to 25,000 hr ng / kg for a 2 mg / kg IV dose or a 10 mg / kg oral dose.
[0126] The indole compounds of the present disclosure can be synthesized by methods known in the art or by methods illustrated in the Examples below.
[0127] The synthesis of phosphate derivatives is described in U.S. Provisional Application No. 62 / 734,989, filed September 21, 2018, which is incorporated by reference in its entirety.
[0128] The classes of compounds described and claimed herein were made by the methods described and tested in a variety of in vitro incubations and in vivo tests in rats, dogs, and monkeys.
[0129] The compounds described herein may contain one or more chiral centers, such as ARI-164, ARI-165, ARI-186, ARI-187, etc. Chirality may confer enhanced potency and in vivo and in vitro stability to these compounds. As discussed in detail in the Examples, some chiral alcohol and chiral amine derivatives of the compounds described herein have demonstrated enhanced potency and reduced susceptibility to cellular oxidation. Furthermore, the enhanced potency and / or stability of many of these chiral compounds was associated with preferred enantiomeric forms.
[0130] In certain embodiments, the present disclosure provides compounds of structural formula 9: [ka] (In the formula: Z1 is N or CR4, Z2 is N or CR5, Z3 is N or CR6, Z4 is N or CR7, Z5 is N or CR8, Z6 is N or C, and Z7 is N or C, where no more than two of Z1, Z2, Z3, Z4, Z5, Z6, and Z7 are N; R4, R5, R6, R7, R8 and R9 each independently represent hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C1-C6 acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R o is hydrogen, deuterium, alkyl, aryl, or acyl; Each R Nis H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Optionally, adjacent R groups may be joined together to form a 3- to 12-membered ring. or an enantiomer, diastereomer or pharmaceutically acceptable salt thereof, comprising: (i) contacting a compound of formula 10 with (S)-2-methylpropane-2-sulfinamide in the presence of a catalyst to obtain a compound of formula 11; [ka] (ii) contacting a compound of formula 11 with one or more alkylating agents to provide a compound of formula 12; [ka] (iii) contacting a compound of formula 12 with a compound of formula 13 in the presence of an organolithium base to obtain a compound of formula 14; [ka] (iv) subjecting the compound of formula 14 to acid-base hydrolysis to obtain the compound of formula 9. This refers to a method including:
[0131] In certain embodiments, R, R, R, R, R, R and R N Each of is hydrogen.
[0132] In certain embodiments, at least one of R4, R5, R6, and R7 is F, Cl, or Br, and the others of R4, R5, R6, and R7 are hydrogen.
[0133] In certain embodiments, R o , R3 and R 3a are independently H or alkyl.
[0134] In certain embodiments, at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N.
[0135] In certain embodiments, the compound of formula 9 is NHR o / R3 / R 3a It is enantiomerically pure at the carbon substituted with .
[0136] In some embodiments, R and R 3a taken together form a 3- to 12-membered ring, such as a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl ring.
[0137] In some embodiments, the catalyst is a transition metal alkoxide.
[0138] In certain embodiments, the transition metal alkoxide is a titanium alkoxide, such as, for example, titanium isopropoxide.
[0139] In some embodiments, the alkylating agent is a metal alkyl, e.g., R 3a MgX alone or R o X or (R o ) 2Zn (wherein X is F, Cl, Br, or I).
[0140] In some embodiments, this method can be used to make other compounds described herein, including compounds of structural formula ARI-179, ARI-186, ARI-187, ARI-218, ARI-219, ARI-226, ARI-232, ARI-233, ARI-234, ARI-235, ARI-236, and the like.
[0141] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention have the meanings commonly understood by those skilled in the art. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present disclosure. In the case of conflict, the present specification, including definitions, will control. Generally, the nomenclature used in and techniques related to cell and tissue culture, molecular biology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, pharmaceutical and medicinal chemistry, and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. Furthermore, unless otherwise required by context, singular terms include pluralities, and plural terms include the singular. Throughout this specification and embodiments, the words "have" and "comprise" or variations such as "has," "having," "comprises," or "comprising" are understood to encompass the inclusion of a stated integer or group of integers and not the exclusion of any other integer or group of integers. All publications and other references mentioned herein are incorporated by reference in their entirety. Although several documents are cited herein, this citation does not constitute an admission that any of these documents form part of the common general knowledge in the art.
[0142] In order that this invention may be better understood, the following examples are set forth. These examples are for illustrative purposes only and are not to be construed as limiting the scope of the invention in any way. [Example]
[0143] Example Example 1: Preparation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123A, ARI-164) and (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123B, ARI-165) [ka] Step 1. Preparation of (6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123, ARI-161) [ka] To an ice-cold suspension of 1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propan-1-one (ARI-143; 4.0 g, 13.2 mmol) in EtOH / THF (50 mL / 50 mL) was added sodium borohydride (503 mg, 13.2 mmol) dropwise, and the reaction mixture was stirred for 1 h. Upon complete consumption of the starting material as indicated by TLC, the mixture was quenched with acetone (2 mL) and concentrated to remove the organic solvent. The residue was then diluted with water (100 mL) and subsequently extracted with EtOAc (100 mL×4). The combined organic phases were washed with brine, dried, and concentrated. Trituration of the residue with EtOAc / hexane afforded (6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (3.9 g, 97% yield).
[0144] Step 2. Preparation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123A, ARI-164) and (R)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl acetate (Ac-ARI-165) [ka] To a room temperature solution of (6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (6.0 g, 19.7 mmol) and vinyl acetate (8.5 g, 99 mmol) in acetone (200 mL) was added Novozym 435 (6.0 g, 10,000 PLU / g) and the resulting suspension was stirred for 48 h at 25° C. Upon completion, the mixture was filtered and the filtrate was concentrated. Purification of the residue by silica gel column chromatography (hexane / EtOAc = 3:1 to 1:1) gave (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (2.3 g, 38% yield) and (R)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl acetate (2.8 g, 41% yield) as yellow solids. ARI-164: 1 H-NMR (400 MHz, DMSO-d6): δ 12.24 (bs, 1H), 9.11 (s, 1H), 8.28–8.32 (dd, J = 5.6 and 9.6 Hz, 1H), 7.83 (s, 1H), 7.37–7.41 (dd, J = 2.4 and 9.6 Hz, 1H), 7.11–7.18 (m, 1H), 5.48 (m, 1H), 4.74 (m, 1H), 1.90–2.00 (m, 1H), 1.75–1.83 (m, 1H), 0.93 (t, J = 7.2 Hz, 3H). LC-MS: m / z 302.9 [M−H] - Chiral HPLC purity: 100% (Rt 10.826min) Optical rotation: -39.7°(CH3CN, c = 0.310, 20℃)
[0145] Step 3. Preparation of (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123B, ARI-165) [ka] Lithium hydroxide monohydrate (0.8 g, 19 mmol) was added to an ice-cold solution of (R)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl acetate (2.0 g, 5.8 mmol) in THF (10 mL) and HO (10 mL). The resulting mixture was stirred at room temperature for 2 h, then acidified with 1 M aqueous HCl to a pH of 6, and then extracted with EtOAc (20 mL x 3). The combined organic phases were washed with brine, dried over NaSO, filtered, and concentrated to dryness. Trituration of the residue with EtOAc / hexane (1:5, 20 mL), followed by filtration and drying, afforded (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.5 g, 85% yield) as a yellow solid. ARI-165: 1H-NMR (400 MHz, DMSO-d6): δ 12.25 (bs, 1H), 9.11 (s, 1H), 8.28-8.32 (dd, J = 5.6 and 9.6 Hz, 1H), 7.84 (s, 1H), 7.37-7.41 (dd, J = 2.4 and 9.6 Hz, 1H), 7.11-7.18 (m, 1H), 5.46-5.50 (m, 1H), 4.72-4.76 (t, J = 6.0 Hz, 1H), 1.89-1.99 (m, 1H), 1.76-1.85 (m, 1H), 0.92-0.96 (t, J = 7.2 Hz, 3H). LC-MS: m / z 302.9 [M−H] - Chiral HPLC purity: 97.9% (Rt 13.547min) Optical rotation: +40.3° (CH3CN, c = 0.330, 20℃)
[0146] Example 2: Separation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123A, ARI-164) and (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (PTC17341-123B, ARI-165) by SFC SFC separation of racemic (6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (4.9 g) derived from the reduction of 1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propan-1-one (ARI-143; 5.5 g) gave (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.60 g, 100% ee, 33% yield) and (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.75 g, 96.7% ee, 37% yield).
[0147] Example 3 Preparation of (S)-(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (PTC17341-16A, ARI-092) and (R)-(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (PTC17341-16A, ARI-094) [ka] Step 1. Preparation of (4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (PTC17341-16) [ka] To an ice-cooled suspension of 1-(2-(1H-indole-3-carbonyl)thiazol-4-yl)propan-1-one (ARI-002; 1.4 g, 5 mmol) in EtOH / THF (50 mL / 50 mL) was added sodium borohydride (190 mg, 5 mmol), and the mixture was stirred for 1 h. Upon complete consumption of the starting material as indicated by TLC, the mixture was quenched with acetone (2 mL) and concentrated to remove the organic solvent. The residue was then diluted with water (100 mL) and subsequently extracted with EtOAc (100 mL x 4). The combined organic phases were washed with brine, dried, and concentrated. Purification of the residue by silica gel column chromatography (hexane / EtOAc = 2:1 to 1:1) afforded racemic (4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (690 mg, 49% yield).
[0148] Step 2. Chiral separation of (4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (PTC17341-16) into (S)(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-yl)methanone (PTC17341-16A, ARI-092) and (R)(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (PTC17341-16B, ARI-094) Separation of racemic (4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (690 mg) by chiral prep-HPLC gave (S)(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-yl)methanone (115 mg, 100% ee, 173% yield, Rt 12.138 min) and (R)(4-(1-hydroxypropyl)thiazol-2-yl)(1H-indol-yl)methanone (135 mg, 96.7% ee, 19% yield, Rt 15.243 min).
[0149] Example 4: Chiral synthesis of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (ARI-164; major product) and (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (ARI-165; minor product) To an ice-cold solution of 1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propan-1-one (150 mg, 0.5 mmol) in THF (20 mL) was added (R)-(+)-2-methyl-CBS-oxazaborolidine (1 M in toluene, 0.1 mL, 0.1 mmol), followed by the dropwise addition of BH3-THF solution (1 M, 0.5 mL, 0.5 mmol). The reaction mixture was stirred at 0 °C for 3 h, allowed to warm to room temperature, and then stirred overnight. The mixture was quenched with acetone (2 mL) and concentrated to remove the organic solvent. The residue was then diluted with water (100 mL) and subsequently extracted with EtOAc (100 mL × 4). The combined organic phase was washed with brine, dried, and concentrated. The residue was purified by silica gel column chromatography (hexane / EtOAc = 3:1 to 1:1) to give the compound (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (50 mg, 34% yield, 93.5% chiral HPLC purity).
[0150] Example 5: Preparation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-methoxypropyl)thiazolyl)methanone (PTC17341-138; ARI-184) [ka] To an ice-cold solution of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.0 g, 3.3 mmol) and tetrafluoroboric acid (50% aqueous, 0.1 mL) in THF (50 mL) was added dropwise a freshly prepared diazomethane solution (in ethyl ether, 50 mmol). Upon complete consumption of the starting material, as indicated by TLC, the reaction mixture was quenched with acetic acid (0.5 mL) and then concentrated to remove the organic solvent. The resulting residue was diluted with water (100 mL) and then extracted with EtOAc (100 mL×4). The combined organic phase was washed with brine, dried, and concentrated. Purification of the residue by silica gel column chromatography (hexane / EtOAc = 3:1 to 1:1) afforded (S)-(6-fluoro-1H-indol-3-yl)(4-(1-methoxypropyl)thiazolyl)methanone (550 mg, 52% yield) as a yellow solid. 1 H-NMR (400 MHz, DMSO-d6): δ 12.24 (bs, 1H), 9.05 (s, 1H), 8.27~8.33 (dd, J = 5.6 and 8.4 Hz, 1H), 7.95 (s, 1H), 7.38~7.41 (d, J = 9.2 Hz, DEPT135 (100 MHz, DMSO-d6): δ 138.80, 123.00, 122.83, 111.32, 99.65, 99.39, 80.63, 66.79, 28.29, 10.13 LC-MS: m / z 318.9 [M+H] + ; Chiral HPLC purity: 99.8% (Rt 24.148 min)
[0151] Example 6: Preparation of (R)-(6-fluoro-1H-indol-3-yl)(4-(1-methoxypropyl)thiazol-2-yl)methanone (PTC17341-139; ARI-178) [ka] (R)-(6-Fluoro-1H-indol-3-yl)(4-(1-methoxypropyl)thiazol-2-yl)methanone (450 mg, 45% yield) was synthesized according to the method described in Example 5, except that (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone was used instead of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone. 1 H-NMR (400 MHz, DMSO-d6): δ 12.24 (bs, 1H), 9.04–9.06 (d, J = 2.8, 1H), 8.27–8.30 (dd, J = 6.0 and 8.8 Hz, 1H), 7.95 (s, 1H), 7.38–7.41 (dd, J = 2.8 and 9.2 Hz, 1H), 7.11–7.18 (m, 1H), 4.40–4.43 (m, 1H), 3.26 (s, 3H), 1.89–1.95 (m, 2H), 0.86–0.93 (t, J = 7.2 Hz, 3H). LC-MS: m / z 316.9 [M−H] - (Chiral HPLC purity: 98.1% (Rt 25.706 min)
[0152] Example 7: Preparation of PTC17341-133A (R)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-133A; ARI-187) [ka] Step 1. Preparation of (R)-tert-butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (1) [ka] (S)-(6-Fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.6 g, 5 mmol) and BocO (1.2 g, 5.6 mmol) were dissolved in THF (50 mL), and then DMAP (20 mg, cat.) and TEA (2 mL) were added. The resulting mixture was stirred at room temperature for 12 min, then diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were then washed with 1N aqueous HCl (100 mL x 2) and brine, dried over magnesium sulfate, and concentrated to give Boc-ARI-165 (1.65 g), which was used without further purification.
[0153] Then, to an ice-cold solution of triphenylphosphine (1.6 g, 6.4 mmol), compound Boc-ARI-165 (1.65 g, 4 mmol), and phthalimide (0.8 g, 5 mmol) in THF (40 mL) was added dropwise DIAD (1.2 g, 6 mmol). After stirring at 0 °C for 1 h, the reaction mixture was warmed to room temperature and stirred for an additional 16 h. The reaction mixture was then concentrated, diluted with ethyl acetate (100 mL), washed with water (100 mL x 2) and then with a 5% solution of sodium bisulfate (100 mL x 2), dried, and concentrated to dryness. Purification of the residue by flash chromatography (hexane / EtOAc = 5:1 to 3:1) gave (R)-tert-butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (520 mg, 19% yield).
[0154] Step 2. Preparation of (R)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-133A; ARI-187) [ka] (R)-tert-Butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (500 mg, 0.94 mmol) was suspended in hydrazine hydrate (80% solution, 60 mL) and EtOH (15 mL), and the resulting mixture was heated under reflux for 10 h. The reaction mixture was then cooled to room temperature and subsequently filtered. The filtrate was concentrated to dryness, and trituration of the residue with EtOAc / hexanes afforded the compound (R)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (160 mg, 56% yield) as a yellow solid. 1 H-NMR (400 MHz, DMSO-d6): δ 9.15 (s, 1H), 8.26–8.33 (dd, J = 5.6 and 8.4 Hz, 1H), 7.86 (s, 1H), 7.34–7.39 (dd, J = 2.4 and 9.6 Hz, 1H), 7.11–7.17 (m, 1H), 4.02–4.06 (t, J = 6.4 Hz, 2H), 1.82–1.95 (m, 1H), 1.70–1.80 (m, 1H), 0.88–0.93 (t, J = 7.2 Hz, 3H). LC-MS: m / z 303.9 [M+H] + ; Chiral HPLC purity: 100% (Rt 12.890 min).
[0155] Example 8: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-133B; ARI-186) [ka] Step 1. Preparation of (S)-tert-butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (2) [ka] (S)-tert-Butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate was synthesized according to the method described in Step 1 of Example 7, except that (R)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone was used instead of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone.
[0156] Step 2. Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-133B) [ka] (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (410 mg, 78% yield) was synthesized according to the method described in Step 3 of Example 7, except that (S)-tert-butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate was used instead of (R)-tert-butyl 3-(4-(1-(1,3-dioxoisoindolin-2-yl)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate. 1H-NMR (400 MHz, DMSO-d6): δ 9.11 (s, 1H), 8.25–8.30 (dd, J = 5.6 and 8.8 Hz, 1H), 7.90 (s, 1H), 7.34–7.38 (dd, J = 2.4 and 9.6 Hz, 1H), 7.08–7.14 (m, 1H), 3.94–3.99 (t, J = 6.4 Hz, 2H), 1.82–2.00 (m, 1H), 1.68–1.74 (m, 1H), 0.83–0.93 (t, J = 7.2 Hz, 3H); LC-MS: m / z 304.0 [M+H] + Chiral HPLC purity: 100% (Rt 11.890 min)
[0157] Example 9: Preparation of (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-morpholinobutanoate hydrochloride (ARI-197) [ka] To an ice-cold solution of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (4.09 g, 13.44 mmol) in THF (67.2 mL) and pyridine (6.52 mL, 81 mmol), 4-bromobutanoyl chloride (1.968 mL, 16.13 mmol) was added dropwise via syringe over 5-10 min. After 5 min, the cooling bath was removed and the reaction was allowed to warm slowly to ambient temperature. LC-MS (ESI-MS: m / z 453 / 455 [M+H] + Upon completion, as determined by ), the reaction mixture was concentrated under reduced pressure without heating and then partitioned between EtOAc and saturated aqueous NaHCO. The organic phase was washed with brine, dried over NaSO, filtered, and concentrated to a yellow solid. The solid was co-evaporated with two portions of toluene, briefly placed under high vacuum, and then used without further purification.
[0158] To a solution of crude (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-bromobutanoate (13.44 mmol) in DMF (25 mL) was added morpholine (7.05 mL, 81 mmol). LC-MS (ESI-MS: m / z 460 [M+H] + Upon completion of the reaction, as determined by HCl, the reaction mixture was poured into a saturated aqueous solution of NaHCO3 and then extracted with EtOAc. The organic phase was washed with water, then brine, dried over Na2SO4, and filtered. Celite was added to the filtrate, and the mixture was concentrated to dryness. Chromatographic separation (330 g silica gel, CHCl2 to 40%, 80:18:2 CHCl2:MeOH:NH4OH) afforded the amine free base (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-morpholinobutanoate as a yellow solid. The solid was placed under high vacuum for several hours and then dissolved in CHCl2 (50 mL). To this solution was added a slight excess of HCl (4 N in dioxane; 3.70 mL, 14.78 mmol) (acidity confirmed by pH paper) with stirring. The reaction mixture was concentrated to dryness under reduced pressure to afford a yellow solid. A smaller batch (3.29 mmol) of the free base, previously prepared using the same procedure, was combined at this point. The combined batches were dissolved in water and acetonitrile, filtered through a 0.2 micron nylon filter, and then lyophilized to give (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-morpholinobutanoate hydrochloride (7.53 g, 15.19 mmol) as a pale yellow solid. The overall yield (16.73 mmol total) from the alcohol was 90%. ARI-197: 1H NMR (500 MHz, DMSO-d6) δ 12.30 (s, 1H), 10.07 (br. s, 1H), 9.03 (d, J = 3.1 Hz, 1H), 8.29 (dd, J = 8.7, 5.7 Hz, 1H), 8.04 (s, 1H), 7.40 (dd, J = 9.5, 2.3 Hz, 1H), 7.17-7.12 (m, 1H), 5.95 (t, J = 6.6 Hz, 1H), 3.94 (d, J = 12.5 Hz, 2H), 3.68 (t, J = 12.4 Hz, 2H), 3.41 (d, J = 12.4Hz, 2H), 3.13-3.08 (m, 2H), 3.06-2.97 (m, 2H), 2.56 (app t, 7.07 Hz, 2H), 2.15-1.92 (m, 4H), 0.93 (t, J = 7.1 Hz, 3H); 19 F NMR (470 MHz, D2O) δ -118.22; ESI-MS: m / z 460 [M+H] + ; Specific optical rotation: -67.8° (CH3CN, c = 0.12, 20℃).
[0159] Example 10: Preparation of (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-(4-methylpiperazin-1-yl)butanoate dihydrochloride (ARI-196) [ka] (S)-1-(2-(6-Fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-(4-methylpiperazin-1-yl)butanoate dihydrochloride (902 mg, 1.65 mmol) was synthesized from (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (1.046 g, 3.44 mmol) according to the method described in Example 9, except that 1-methylpiperazine was used instead of morpholine. ARI-196:1 H NMR (500 MHz, D2O) δ 8.68 (s, 1H), 8.15 (dd, J = 8.8, 5.5 Hz, 1H), 7.83 (s, 1H), 7.28 (dd, J = 9.5, 2.1 Hz, 1H), 7.13-7.09 (m, 1H), 5.87 (t, J = 6.8 Hz, 1H), 3.30 (br m, 9H), 2.96-2.93 (m, 1H), 2.81 (s, 3H), 2.50 (app t, J = 7.0 Hz, 2H), 2.07-2.01 (m, 2H), 1.94-1.88 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); 19 F NMR (470 MHz, D2O) δ -118.24; ESI-MS: m / z 473 [M+H] + ; Specific optical rotation: -63.6° (CH3CN, c = 0.055, 20℃). C 24 H 29 Elemental Analysis of FN4O3S·2HCl·1.45 H2O: Theory: C-50.43; H-5.98; Cl-12.4; N-9.8. Experiment: C-50.16; H-5.67; Cl-12.56; N-9.68.
[0160] Example 11: Preparation of (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-(dimethylamino)butanoate hydrochloride (ARI-198) [ka] (S)-1-(2-(6-Fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-(dimethylamino)butanoate hydrochloride (125 mg, 0.275 mmol, 53% yield) was synthesized from (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (0.512 mmol) according to the method described in Example 9, except that dimethylamine (2 M in THF) was used instead of morpholine. ARI-198: 1 H NMR (500 MHz, D2O) δ 8.65 (s, 1H), 8.12 (dd, J = 8.9, 5.4 Hz, 1H), 7.81 (s, 1H), 7.25 (dd, J = 11.8, 2.2 Hz, 1H), 7.10-7.06 (m, 1H), 5.87 (t, J = 7.2 Hz, 1H), 3.02 (dd, J = 9.4, 6.8 Hz, 2H), 2.72 (s, 6H), 2.51 (dt, J = 10.4, 2.8 Hz, 2H), 2.06-2.01 (m, 2H), 1.97-1.91 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); 19 F NMR (470 MHz, D2O) δ -118.35; ESI-MS: m / z 418 [M+H] + .
[0161] Example 12: Preparation of ((S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-([1,4'-bipiperidin]-1'-yl)butanoate dihydrochloride (ARI-199) [ka] (S)-1-(2-(6-Fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 4-(dimethylamino)butanoate dihydrochloride (204 mg, 0.329 mmol, 96% yield) was synthesized from (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (0.493 mmol) according to the method described in Example 9, except that 4-piperidinopiperidine was used instead of morpholine. ARI-199: 1 H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 10.23 (br. s, 1H), 10.11 (br. s, 1H), 9.03 (d, J = 3.1 Hz, 1H), 8.29 (dd, J = 8.8, 5.7 Hz, 1H), 8.04 (s, 1H), 7.40 (dd, J = 9.5, 2.4 Hz, 1H), 7.17-7.12 (m, 1H), 5.95 (t, J = 6.6 Hz, 1H), 3.61 (d, J = 11.0 Hz, 2H), 3.42-3.34 (m, 2H), 3.08-3.01 (m, 2H), 2.98-2.85 (m, 4H), 2.59-2.53 (m, 2H), 2.26 (d, J = 13.1 Hz, 2H), 2.15-1.94 (m, 6H), 1.84-1.65 (m, 5H), 1.46-1.35 (m, 1H), 0.93 (t, J = 7.3 Hz, 3H); 19 F NMR (470 MHz, DMSO-d6) δ -118.59; ESI-MS: m / z 541 [M+H] + .
[0162] Example 13: Preparation of (S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 2-morpholinoacetate hydrochloride (ARI-205) [ka] (S)-1-(2-(6-Fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl 2-morpholinoacetate hydrochloride was synthesized from (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone according to the method described in Example 9, except that chloroacetyl chloride was used instead of 4-bromobutanoyl chloride. ARI-205: 1 H NMR (500 MHz, DMSO-d6) δ 12.33 (br. s, 1H), 10.79 (br. s, 1H), 9.03 (d, J = 3.2 Hz, 1H), 8.29 (dd, J = 8.8, 5.6 Hz, 1H), 8.14 (s. 1H), 7.44 (dd, J = 9.5, 2.2 Hz, 1H), 7.18 - 7.12 (m, 1H), 6.12 - 6.02 (m, 1H), 4.63 - 2.94 (Obs. m, 10H, Morpholine), 2.21 - 2.03 (m, 1H), 0.95 (t, J = 7.3 Hz, 3H); 19 F NMR (470 MHz, DMSO-d6) δ -118.58; ESI MS m / z 430 [MH] - .
[0163] Example 14: Preparation of sodium (S)-5-(1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propoxy)-5-oxopentanoate (ARI-192) [ka] Pyridine (0.12 mL, 1.484 mmol) was added to a mixture of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (105 mg, 0.345 mmol) and glutaric anhydride (39.4 mg, 0.345 mmol), and the resulting solution was heated to 60 °C. Upon completion, the reaction mixture was treated with 1:1 MeOH / HO (10 mL), followed by the addition of 1.5 mL of saturated aqueous NaHCO. The solution was then concentrated using MeOH, and the sample was adsorbed onto Celite. Chromatographic separation (100 g C18, 10% CHCN / HO to CHCN + 0.1% TFA, dry loaded Celite) afforded the product as a pale yellow solid, which was contaminated with TFA. The material was then combined with another previous batch (50 mg), which was also contaminated with TFA. The combined material was adsorbed onto Celite using MeOH. Further chromatographic separation (100 g C18, 10% CH3CN / H2O to CH3CN, dry loaded Celite) gave the product, which was then taken up in 1:1 MeOH / H2O and washed with Dowex 50Wx8, Na + The resulting solution was passed through 50-100 mesh ion exchange resin (1.5 g, 0.191 mmol) in the form of a 50-100% methyl methyl ether. The residue was concentrated and lyophilized from HO / CHCN to give sodium (S)-5-(1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propoxy)-5-oxopentanoate (84 mg, 0.191 mmol) as a yellow solid. The overall yield was 24% from 0.789 mmol of alcohol. ARI-192: 1H NMR (500 MHz, DMSO-d6) δ 12.63 (br. s, 0.5 H), 12.08 (br. s, 0.5 H), 9.04 (s, 1H), 8.27 (dd, J = 8.7, 5.6 Hz, 1H), 8.00 (s, 1H), 7.37 (dd, J = 9.6, 2.2 Hz, 1H), 7.15 - 7.11 (m, 1H), 5.93 (dd, J = 7.4, 5.6 Hz, 1H), 2.47 - 2.44 (obscure m, 2H), 2.23 (app t, J = 7.3 Hz, 2H), 2.14 - 1.95 (m, 2H), 1.81 - 1.75 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); 19 F NMR (470 MHz, D2O) δ -118.38; ESI-MS: m / z 419 [M+H] + .
[0164] Example 15: Preparation of sodium (S)-(4-(1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propoxy)-4-oxobutyl)phosphonate (ARI-193) [ka] Step 1. To an ice-cold suspension of 4-phosphobutanoic acid (168 mg, 0.999 mmol) in CHCl (5 mL) was added oxalyl chloride (0.338 mL, 4.00 mmol), followed by 2 drops of DMF. After 3 h, effervescence ceased and the solvent was evaporated to a solid. The solid was co-evaporated with toluene, dried under high vacuum, and then used directly as is.
[0165] Step 2. To an ice-cold solution of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-hydroxypropyl)thiazol-2-yl)methanone (215 mg, 0.706 mmol) in THF (10 mL) and pyridine (0.457 mL, 5.65 mmol) was added dropwise 5.67 mL of the reagent prepared in Step 1 (23.25 mg / mL in 3:1 THF:DCM) (132 mg, 0.706 mmol). An additional 2 mL of the reagent prepared in Step 1 (23.25 mg / mL in 3:1 THF:DCM) was then added as LC-MS indicated an incomplete reaction. Upon completion, the reaction mixture was treated with water and most of the solvent was concentrated under reduced pressure. The residue was then partitioned between EtOAc and 1N HCl (aq). The organic phase became a thick slurry, which was treated with water and then brine. The emulsion was then filtered using a Buchner funnel, and the solid was allowed to dry on the filter overnight. The EtOAc layer of the filtrate was concentrated, and the resulting residue was recombined with the solid using MeOH. After the addition of water and a saturated aqueous solution of NaHCO3, the mixture was adsorbed onto Celite and then concentrated to dryness. Chromatographic separation (100 g C18, 10% CH3CN / HO to CH3CN, dry loaded Celite) afforded sodium (S)-(4-(1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propoxy)-4-oxobutyl)phosphonate (143 mg, 0.287 mmol) as a yellow solid after lyophilization from water and acetonitrile. ARI-193: 1 H NMR (500 MHz, D2O) δ 8.61 (s, 1H), 8.14 - 8.11 (m, 1H), 7.80 (s, 1H), 7.30 - 7.28 (m, 1H), 7.09 - 7.05 (m, 1H), 5.85 (t, J = 6.86 Hz, 1H), 2.30 (app t, J = 7.6 Hz, 2H), 2.02 - 1.97 (m, 2H), 1.85 - 1.76 (m, 2H), 1.44 - 1.37 (m, 2H), 0.87 (t, J = 7.3 Hz, 3H); ); 31P NMR (202 MHz, D2O) δ 21.47; 19 F NMR (470 MHz, D2O) δ -118.50; ESI-MS: m / z 453 [MH] - .
[0166] Example 16: Preparation of 2-(2-(1H-indole-3-carbonyl)thiazol-4-yl)-2-aminoacetonitrile [ka] Step 1: Preparation of tert-butyl 3-(4-(amino(cyano)methyl)thiazole-2-carbonyl)-1H-indole-1-carboxylate (93-1) [ka] Trimethylsilyl cyanide (0.74 mL, 5.5 mmol) was added to a solution of tert-butyl-3-(4-formylthiazole-2-carbonyl)-1H-indole-1-carboxylate (1.40 g, 4 mmol) in THF (5 mL) and NH3-MeOH (7 M solution, 20 mL) at room temperature. The mixture was stirred for 2 h and then concentrated to dryness to give compound 93-1 (2.0 g, approximately 100% yield), which was used in the next step without further purification.
[0167] Step 2: Preparation of 2-(2-(1H-indole-3-carbonyl)thiazol-4-yl)-2-aminoacetonitrile (ARI-075) [ka] Compound 93-1 (2.00 g, 5 mmol) was dissolved in TFA / DCM (10 mL / 10 mL) at 0° C. The mixture was then warmed to room temperature and stirred for 2 h. The mixture was then concentrated to dryness. The residue was suspended in saturated aqueous KHCO (50 mL) and EtOAc (50 mL) and stirred for 0.5 h, then filtered to collect the solid. The solid was washed with water (30 mL×3) and EtOAc (30 mL×3) and dried to give compound ARI-075 (680 mg, 43% yield) as a yellow solid. 1 H-NMR (400 MHz, DMSO-d6): δ 12.37 (bs, 1H), 9.17 (s, 1H), 8.31~8.35 (m, 1H), 8.07 (s, 1H), 7.56~7.59 (d, J = 6.0 Hz, 1H), 7.28~7.33 (m, 2H), 5.34~5.39 (t, J = 8.0 Hz, 1H), 3.05~3.08 (d, J = 8.0 Hz, 1H). LC-MS: m / z 281.0 [M−H] - .
[0168] Example 17: Preparation of 2-amino-2-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)acetonitrile (ARI-173) [ka] 2-Amino-2-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)acetonitrile was synthesized according to the method described in Example 16, except that tert-butyl-3-(4-formylthiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate was used instead of tert-butyl-3-(4-formylthiazole-2-carbonyl)-1H-indole-1-carboxylate. 1H-NMR (400 MHz, DMSO-d6): δ 12.15 (bs, 1H), 9.17 (s, 1H), 8.28–8.32 (dd, J = 5.6 and 8.8 Hz, 1H), 8.08 (s, 1H), 7.37–7.41 (dd, J = 2.0 and 8.8 Hz, 1H), 7.12–7.19 (m, 1H), 5.33–5.39 (t, J = 8.4 Hz, 1H), 3.06–3.08 (d, J = 8.4, 2H). LC-MS: m / z 298.9 [M−H]-.
[0169] Example 18: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-hydroxybutan-2-yl)thiazol-2-yl)methanone (PTC17341-143; ARI-209) [ka] Step 1: Preparation of 2-(thiazol-4-yl)butan-2-ol (143-1) [ka] A solution of 1-(thiazol-4-yl)propan-1-one (3.0 g, 21 mmol) in THF (100 mL) was stirred and cooled to -10 °C under N. Then, MeMgI (3 M in EtO, 33 mL, 0.1 mol) was added dropwise over 30 min at 0–10 °C. The mixture was warmed to room temperature and stirred for 2 h, then quenched with saturated aqueous NH.sub.4Cl (100 mL). The mixture was extracted with EtOAc (100 mL x 3). The combined organic phase was washed with brine (100 mL x 2), dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / hexane = 1:5) to give 2-(thiazol-4-yl)butan-2-ol (1.9 g, 57% yield) as an oil.
[0170] Step 2: Preparation of (S)-4-(2-(triethylsilyloxy)butan-2-yl)thiazole (143-2) [ka] Compound 143-1 (1.9 g, 12.08 mmol) was dissolved in DCM (21 mL) and cooled to 0 °C. Imidazole (1.33 g, 19.9 mmol) was added, followed by the dropwise addition of a solution of TES-Cl (2.2 g, 14.6 mmol) in DCM (8 mL) at 0-20 °C. The reaction mixture was stirred overnight at room temperature and then washed with water, aqueous 5% KHSO (x3), saturated aqueous NaHCO (x3), and brine, dried over anhydrous NaSO, and concentrated to dryness. The residue was purified by distillation under reduced pressure to give compound 143-2 (2.5 g, 76% yield) as an oil.
[0171] Step 3: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-(triethylsilyloxy)butan-2-yl)thiazol-2-yl)methanone (143-3) [ka] A solution of 143-2 (1.45 g, 5.34 mmol) in THF (13 mL) and toluene (13 mL) was cooled to −78° C., and sec-BuLi (1.3 M solution in hexane, 5.1 mL, 6.6 mmol) was added dropwise at −78° C. over 10 min. The mixture was stirred at this temperature for 0.5 h, and then a solution of compound tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (2.15 g, 6.68 mmol) in THF (14 mL) was added dropwise over 10 min. The mixture was stirred at −78° C. for 1 h, then warmed to 0° C. and quenched with aqueous 10% NH4Cl. The organic phase was collected, washed with water (×2), saturated aqueous NaHCO3 (×2), and brine (×1), dried (Na2SO4), filtered, and concentrated to dryness. The residue was dissolved in MeOH and K2CO3 (0.74 g, 5.34 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was filtered and the filtrate was concentrated to dryness. The residue was triturated with EtOH to give compound 143-3 (1.5 g, 65% yield).
[0172] Step 4: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-hydroxybutan-2-yl)thiazol-2-yl)methanone (PTC17341-143; ARI-209) [ka] Tetrabutylammonium fluoride trihydrate (TBAF, 9.0 g, 28.7 mmol) was added to a solution of compound 143-3 (1.5 g, 3.5 mmol) in THF (15 mL) at room temperature. The mixture was stirred at room temperature for 10 h and then quenched with HO. The mixture was extracted with EtOAc (x3). The organic phases were collected, washed with water (x2), saturated aqueous NaHCO (x2), and brine, dried over NaSO, filtered, and concentrated to dryness. The residue was recrystallized from EtOH / HO (9:1) to give compound PTC17341-143 (ARI-209; 735 mg, 66% yield) as a yellowish solid. 1 H-NMR (400 MHz, DMSO-d6): δ 12.21 (bs, 1H), 9.09 (s, 1H), 8.28–8.32 (dd, J = 5.6 and 8.8 Hz, 1H), 7.80 (s, 1H), 7.37–7.40 (dd, J = 2.4 and 9.6 Hz, 1H), 7.11–7.17 (m, 1H), 5.23 (bs, 1H), 1.81–2.00 (m, 2H), 1.54 (s, 3H), 0.75–0.80 (t, J = 7.2 Hz, 3H). LC-MS: m / z 341.0 [M+Na] + .
[0173] Example 19: Preparation of (6-fluoro-1H-indol-3-yl)(4-(3-hydroxypentan-3-yl)thiazol-2-yl)methanone (PTC17341-142; ARI-210) [ka] (6-Fluoro-1H-indol-3-yl)(4-(3-hydroxypentan-3-yl)thiazol-2-yl)methanone was synthesized according to the method described in Example 18, except that EtMgI was used instead of MeMgI. 1 H-NMR (400 MHz, DMSO-d6): δ 12.19 (bs, 1H), 9.05 (s, 1H), 8.29–8.32 (dd, J = 5.6 and 8.8 Hz, 1H), 7.78 (s, 1H), 7.37–7.41 (dd, J = 2.4 and 8.8 Hz, 1H), 7.11–7.18 (m, 1H), 4.97 (bs, 1H), 1.91–2.00 (m, 2H), 1.77–1.87 (m, 2H), 0.72–0.77 (m, 6H).
[0174] Example 20: Preparation of (1H-indol-3-yl)(4-(2-hydroxypropan-2-yl)thiazol-2-yl)methanone (PTC17341-157; ARI-215) [ka] Step 1: Preparation of thiazole-4-carbonitrile (157-1) [ka] A solution of N-methoxy-N-methylthiazole-4-carboxamide (17.2 g, 0.10 mol) in THF (500 mL) was stirred and cooled to -10 °C under N. Then, MeMgI (3 M in EtO, 200 mL, 0.60 mol) was added dropwise over 30 min at 0–10 °C. The mixture was warmed to room temperature and stirred for 2 h, then quenched with saturated aqueous NH.sub.4Cl (500 mL). The mixture was extracted with EtOAc (500 mL x 3). The combined organic phases were washed with brine (500 mL x 2), dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / hexane = 1:5) to give compound 157-1 (9.3 g, 65% yield) as an oil.
[0175] Step 2: Preparation of 4-(2-(triethylsilyloxy)propan-2-yl)thiazole (157-2) [ka] 157-1 (9.4 g, 65.6 mmol) was dissolved in DCM (113 mL) and cooled to 0 °C. Imidazole (72.0 g, 1.06 mol) was added, followed by the dropwise addition of a solution of TES-Cl (11.9 g, 79 mmol) in DCM (85 mL) at 0-20 °C. The reaction mixture was stirred overnight at room temperature and then washed with water, aqueous 5% KHSO (x3), saturated aqueous NaHCO (x3), and brine, dried over anhydrous NaSO, and concentrated to dryness. The residue was purified by distillation under reduced pressure to give compound 157-2 (9.6 g, 57% yield) as an oil.
[0176] Step 3: Preparation of (1H-indol-3-yl)(4-(2-(triethylsilyloxy)propan-2-yl)thiazol-2-yl)methanone (157-3) [ka] A solution of 4-(2-(triethylsilyloxy)propan-2-yl)thiazole (7.2 g, 28 mmol) in THF (8 mL) and toluene (8 mL) was cooled to −78° C., and sec-BuLi (1.3 M solution in hexane, 28 mL, 36.4 mmol) was added dropwise over 10 min at −78° C. The mixture was stirred at this temperature for 0.5 h, and then a solution of tert-butyl 3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (10.65 g, 35 mmol) in THF (100 mL) was added dropwise over 10 min. The mixture was stirred at −78° C. for 1 h, warmed to 0° C., and quenched with aqueous 10% NH4Cl. The organic phase was collected, washed with water (×2), saturated aqueous NaHCO3 (×2), and brine, dried (Na2SO4), filtered, and concentrated to dryness. The residue was dissolved in MeOH and K2CO3 (3.87 g, 28 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was filtered and the filtrate was concentrated to dryness. The residue was triturated with EtOH to give compound 157-3 (6.5 g, 58% yield).
[0177] Step 4: Preparation of (1H-indol-3-yl)(4-(2-hydroxypropan-2-yl)thiazol-2-yl)methanone (PTC17341-157) [ka] Tetrabutylammonium fluoride trihydrate (TBAF, 9.0 g, 28.7 mmol) was added to a solution of compound 157-3 (4.8 g, 11.5 mmol) in THF (50 mL) at room temperature, and the mixture was stirred at room temperature for 10 h and then quenched with HO (100 mL). The mixture was extracted with EtOAc (100 mL x 3). The organic phase was collected and washed with water (500 mL x 2), saturated aqueous NaHCO (100 mL x 2), and brine (100 mL x 1), dried over NaSO, filtered, and concentrated to dryness. The residue was recrystallized from EtOH / HO (9:1, 300 mL) to give compound PTC17341-157 as a yellowish solid. 1H-NMR (400 MHz, DMSO-d6): δ 12.21 (bs, 1H), 9.14–9.15 (d, J = 3.2 Hz, 1H), 8.31–8.34 (dd, J = 4.0 and 8.4 Hz, 1H), 7.81 (s, 1H), 7.55–7.59 (m, 1H), 7.25–7.32 (m, 1H), 5.39 (bs, 1H), 1.58 (s, 6H). LC-MS: m / z 287.0 [M+H] + .
[0178] Example 21: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-hydroxypropan-2-yl)thiazol-2-yl)methanone (ARI-220) [ka] (6-Fluoro-1H-indol-3-yl)(4-(2-hydroxypropan-2-yl)thiazol-2-yl)methanone was synthesized according to the method described in Example 20, except that tert-butyl 3-(methoxy(methyl)carbamoyl)-6-fluoro-1H-indole-1-carboxylate was used instead of tert-butyl 3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate. 1 H-NMR (400 MHz, DMSO-d6): δ 12.19 (bs, 1H), 9.12–9.14 (d, J = 3.2 Hz, 1H), 8.27–8.32 (dd, J = 5.6 and 8.8 Hz, 1H), 7.82 (s, 1H), 7.36–7.40 (dd, J = 2.4 and 8.8 Hz, 1H), 7.10–7.17 (m, 1H), 5.37 (bs, 1H), 1.18 (s, 6H); LC-MS: m / z 303.1 [M−H] - .
[0179] Example 22: Preparation of (6-fluoro-1H-indol-3-yl)(4-(1-hydroxycyclopropyl)thiazol-2-yl)methanone (PTC17341-158; ARI-221) [ka] Step 1: Preparation of 1-(thiazol-4-yl)ethanone (158-1) [ka] A solution of compound N-methoxy-N-methylthiazole-4-carboxamide (110.0 g, 0.643 mol) in THF (1 L) was stirred and cooled to -10 °C under N2, and MeMgBr (1 M) was added dropwise at 0-10 °C over 1 h. The mixture was stirred at this temperature for 2 h and then quenched with saturated aqueous NH4Cl (500 mL). The mixture was warmed to room temperature and then extracted with EtOAc (1 L x 3). The combined organic phases were washed with brine (500 mL x 2), dried, and concentrated to dryness. The residue was purified by distillation under reduced pressure to give compound 158-1 (12.1 g, 69% yield) as an oil.
[0180] Step 2: Preparation of 4-(1-(tert-butyldimethylsilyloxy)vinyl)thiazole (158-2) [ka] tert-Butyldimethylsilyl trifluoromethanesulfonate (TBS-OTf, 15 mL, 56.3 mmol) was added dropwise to a solution of compound 158-1 (5.5 g, 43.3 mmol) and TEA (6.6 g, 65 mmol) in DCM (100 mL) at 0 °C. The reaction mixture was stirred overnight at room temperature, then washed with water (50 mL × 1) and brine (50 mL × 1), dried over anhydrous Na SO , and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / hexane = 1:30) to give compound 158-2 (6.8 g, 65% yield) as an oil.
[0181] Step 3: Preparation of 4-(1-(tert-butyldimethylsilyloxy)cyclopropyl)thiazole (158-3) [ka] Diethylzinc solution (1.0 M in hexane, 15.6 mL, 15.6 mmol) was added dropwise to a solution of compound 158-2 (780 mg, 3.9 mmol) and diiodomethane (4.2 g, 15.6 mmol) in DCM (100 mL) at 0 °C over 10 min. The solution was stirred at 0 °C for 0.5 h and then warmed to room temperature. The mixture was quenched with saturated aqueous NH Cl (50 mL) and extracted with DCM (50 mL × 3). The combined organic layers were washed with brine, dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / hexane = 1:20) to give compound 158-3 (350 mg, 45% yield) as an oil.
[0182] Step 4: Preparation of (4-(1-(tert-butyldimethylsilyloxy)cyclopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (158-4) [ka] A solution of 158-3 (3.23 g, 12.7 mmol) in THF (44 mL) and toluene (44 mL) was cooled to −78° C., and sec-BuLi (1.3 M solution in hexane, 12.1 mL, 15.7 mmol) was added dropwise at −78° C. over 10 min. The mixture was stirred at this temperature for 0.5 h, and then a solution of compound tert-butyl-6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (5.1 g, 15.8 mmol) in THF (43 mL) was added dropwise over 10 min. The mixture was stirred at −78° C. for 1 h, then warmed to 0° C. and quenched with aqueous 10% NH4Cl. The organic phase was collected, washed with water (×2), saturated aqueous NaHCO3 (×2), and brine, dried (Na2SO4), filtered, and concentrated to dryness. The residue was dissolved in MeOH and K2CO3 (1.75 g, 12.7 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated to dryness. The residue was triturated with EtOH to give compound 158-4 (2.9 g, 55% yield) as a yellow solid.
[0183] Step 5: Preparation of (6-fluoro-1H-indol-3-yl)(4-(1-hydroxycyclopropyl)thiazol-2-yl)methanone (PTC17341-158) [ka] Tetrabutylammonium fluoride trihydrate (TBAF, 4.83 g, 17.3 mmol) was added to a solution of compound 158-4 (2.88 g, 6.91 mmol) in THF (30 mL) at room temperature, and the mixture was stirred at room temperature for 10 h and then quenched with HO. The mixture was extracted with EtOAc (x3). The organic phases were collected, washed with water (x2), saturated aqueous NaHCO (x2), and brine, dried (NaSO), filtered, and concentrated to dryness. The residue was recrystallized from EtOH / HO (9:1) to give PTC17341-158 (1.8 g, 86% yield) as a yellow solid. 1H-NMR (400 MHz, DMSO-d6): δ 12.17 (bs, 1H), 8.92 (s, 1H), 8.26–8.30 (dd, J = 5.6 and 8.8 Hz, 1H), 7.80 (s, 1H), 7.35–7.39 (dd, J = 2.4 and 8.8 Hz, 1H), 7.10–7.16 (m, 1H), 6.36 (m, 1H), 1.22–1.30 (m, 2H), 1.18–1.20 (m, 2H); LC-MS: m / z 303.1 [M+H] + .
[0184] Example 23: Preparation of (4-(1-aminocyclopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-159; ARI-225) [ka] Step 1: Preparation of thiazole-4-carbonitrile (159-1) [ka] TEA (76 g, 748 mmol) and TFAA (108 g, 512 mmol) were added to a suspension of thiazole-4-carboxylic acid (21.46 g, 166.2 mmol) in DCM (800 mL) at 0 °C. The mixture was warmed to room temperature and stirred for 6 h, then diluted with HO and EtOAc. The mixture was stirred for 0.5 h and the solid was collected by filtration. The solid was washed with water (x3) and EtOAc (x3) and dried to give compound 159-1 (15.2 g, 83% yield) as an oil.
[0185] Step 2: Preparation of 1-(thiazol-4-yl)cyclopropanamine (159-2) [ka] Titanium(IV) isopropoxide (15.1 mL, 55 mmol) was added to a solution of compound 159-1 (5.5 g, 50 mmol) in THF (100 mL) at 0 °C. The mixture was stirred for 15 min, and then EtMgBr (2 M EtO solution, 50 mL, 0.1 mol) was added dropwise over 30 min at 0 °C. The thick black solution was stirred at room temperature for 2 h, and then BF.EtO (12.5 mL, 0.1 mol) was added dropwise and stirred for 15 min. The reaction was quenched with 1 N aqueous HCl (18 mL), stirred for 30 min, and then alkalized to a pH of 9 with 1 N aqueous NaOH. The mixture was extracted with DCM (200 mL × 3). The combined organic layers were washed with brine, dried and concentrated to dryness to give crude compound 159-2 (3.1 g, 44% yield) as an oil, which was used in the next step without further purification.
[0186] Step 3: Preparation of N,N-diallyl-1-(thiazol-4-yl)cyclopropanamine (159-3) [ka] KOH (7.9 g, 142 mmol) and allyl bromide (19.3 g, 142 mmol) were added to a solution of compound 159-2 (3.1 g, 22 mmol) in DMF (20 mL). The reaction mixture was heated to 60 °C and stirred for 4 h. After cooling to room temperature, the mixture was quenched with HO (50 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with brine, dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / hexane = 1:3) to give compound 159-3 (2.2 g, 45% yield) as an oil.
[0187] Step 4: Preparation of (4-(1-(diallylamino)cyclopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (159-4) [ka] A solution of compound 159-3 (4.43 g, 20.1 mmol) in THF (65 mL) and toluene (65 mL) was cooled to -78 °C, and sec-BuLi (1.3 M solution in hexane, 19.2 mL, 25 mmol) was added dropwise at -78 °C over 10 min. The mixture was stirred at this temperature for 0.5 h, and then a solution of compound tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (8.1 g, 25.1 mmol) in THF (68 mL) was added dropwise over 10 min. The mixture was stirred at -78 °C for 1 h, then warmed to 0 °C and quenched with aqueous 10% NH Cl. The organic phase was collected, washed with water (x2), saturated aqueous NaHCO (x2), and brine, dried (Na SO ), filtered, and concentrated to dryness. The residue was dissolved in MeOH and K2CO3 (2.78 g, 20.1 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated to dryness. The residue was triturated with EtOH to give compound 159-4 (3.3 g, 43% yield) as a yellow solid.
[0188] Step 5: Preparation of (4-(1-aminocyclopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-159) [ka] Pd(PPh3)4(0) (1 g) was added to a solution of compound 159-4 (2.0 g, 4.1 mmol) in DCM (20 mL). Piperidine (2 drops) and AcOH (20 drops) were added, and the mixture was then heated under reflux under N2 for 5 h. After cooling to room temperature, the mixture was concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / DCM / MeOH=10:10:1) to give compound PTC17341-159 in the form of a yellow solid (460 mg, 28% yield). 1H-NMR (400 MHz, DMSO-d6): δ 12.17 (bs, 1H), 8.96 (s, 1H), 8.26–8.29 (dd, J = 5.6 and 8.8 Hz, 1H), 7.84 (s, 1H), 7.34–7.38 (dd, J = 2.4 and 9.6 Hz, 1H), 7.09–7.16 (m, 1H), 2.50 (bs, 2H), 1.74–1.78 (m, 2H), 1.05–1.10 (m, 2H); LC-MS: m / z 302.0 [M+H] + .
[0189] Example 24: Preparation of (4-(2-aminopropan-2-yl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-161; ARI-226) [ka] Step 1: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-(triethylsilyloxy)propan-2-yl)thiazol-2-yl)methanone (161-1) [ka] A solution of 4-(2-(triethylsilyloxy)propan-2-yl)thiazole (10.1 g, 39.3 mmol) in THF (130 mL) and toluene (130 mL) was cooled to −78° C., and sec-BuLi (1.3 M solution in hexanes, 37.4 mL, 48.7 mmol) was added dropwise over 10 min at −78° C. The mixture was stirred at this temperature for 0.5 h, and then a solution of tert-butyl-6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (15.8 g, 49.1 mmol) in THF (130 mL) was added dropwise over 10 min. The mixture was stirred at −78° C. for 1 h, then warmed to 0° C. and quenched with aqueous 10% NH4Cl. The organic phase was collected, washed with water (x2), saturated aqueous NaHCO3 (x2) and brine, dried (Na2SO4), filtered and concentrated to dryness. The residue was dissolved in MeOH and K2CO3 (5.4 g, 39.3 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was filtered and the filtrate was concentrated to dryness. The residue was triturated with EtOH to give compound 161-1 (11.0 g, 67% yield) as a yellow solid.
[0190] Step 2: Preparation of (6-fluoro-1H-indol-3-yl)(4-(2-hydroxypropan-2-yl)thiazol-2-yl)methanone (161-2) [ka] Tetrabutylammonium fluoride trihydrate (TBAF, 9.0 g, 28.7 mmol) was added to a solution of compound 161-1 (4.8 g, 11.5 mmol) in THF (50 mL) at room temperature, and the mixture was stirred at room temperature for 10 h and then quenched with HO (100 mL). The mixture was extracted with EtOAc (100 mL x 3). The organic phase was collected and washed with water (500 mL x 2), saturated aqueous NaHCO (100 mL x 2), and brine (100 mL x 1), dried (NaSO), filtered, and concentrated to dryness. The residue was recrystallized from EtOH / HO (9:1, 300 mL) to give 161-2 (4.9 g, 90% yield) as a yellow solid.
[0191] Step 3: Preparation of N-(2-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propan-2-yl)acetamide (161-3) [ka] A solution of compound 161-2 (3.9 g, 7.5 mmol) in AcOH (40 mL) was cooled to 0 °C. Acetonitrile (1 mL) and conc. H2SO4 (20 mL) were added, and then the mixture was heated to 60 °C and stirred under N2 for 5 h. After cooling to room temperature, the mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine, dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / DCM / THF = 3:3:1) to give compound 161-3 (1.6 g, 62% yield).
[0192] Step 4: Preparation of (4-(2-aminopropan-2-yl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (PTC17341-161) [ka] KOH (2.6 g, 46 mmol) was added to a solution of compound 161-3 (1.6 g, 4.6 mmol) in glycol (50 mL). The mixture was heated to 175 °C and stirred for 8 h. After cooling to room temperature, the mixture was diluted with HO (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine, dried, and concentrated to dryness. The residue was purified by silica gel chromatography (EtOAc / DCM / THF / MeOH = 3:3:1:1) to give compound PTC17341-161 (900 mg, 64% yield) as a yellow solid. 1H-NMR (400 MHz, DMSO-d6): δ 9.15 (s, 1H), 8.27–8.32 (dd, J = 5.6 and 8.8 Hz, 1H), 7.83 (s, 1H), 7.36–7.39 (dd, J = 2.4 and 9.6 Hz, 1H), 7.10–7.16 (m, 1H), 1.49 (s, 6H); LC-MS: m / z 326.0 [M+Na] + .
[0193] Example 25: Preparation of D3-ARI-164 (ARI-217) Step 1: Preparation of D3-ARI-143 [ka] NaOH (2.65 g, 66 mmol) was added to a solution of 1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propan-1-one (2.0 g, 6.6 mmol) in DMSO-d (20 mL) and DO (3 mL). The mixture was heated to 95 °C and stirred for 8 h. After cooling to room temperature, the mixture was diluted with HO (100 mL). The solid was collected and dissolved in DMSO-d (20 mL) and DO (3 mL), and NaOH (2.65 g, 66 mmol) was added. The mixture was heated to 95 °C and stirred for 8 h. This process was repeated 2–3 times until NMR showed a deuteration ratio >99%. The solid was finally collected, washed with EtOAc, and dried to give D3-ARI-143 (1.1 g, 55% yield, 99% deuteration by NMR) as a yellow solid. 1 H-NMR (400 MHz, DMSO-d6): δ 12.35 (bs, 1H), 9.15–9.17 (d, J = 3.2 Hz, 1H), 8.27–8.32 (dd, J = 5.6 and 8.4 Hz, 1H), 7.39–7.42 (dd, J = 2.4 and 9.6 Hz, 1H), 7.13–7.19 (m, 1H), 1.41 (s, 3H); LC-MS: m / z 304.0 [M−H] -.
[0194] Step 2: Preparation of D3-ARI-164 [ka] Compound D3-ARI-143 (150 g, 0.50 mol) was dissolved in THF (1 L). The mixture was cooled to 0 °C, and then (R)-(+)-2-methyl-CBS-oxazaborolidine (1 M in toluene, 100 mL, 0.1 mol) was added, followed by the dropwise addition of BH3-THF solution (1 M, 500 mL, 0.5 mol) over 2 h. The mixture was stirred at 0 °C for 3 h, then warmed to room temperature and stirred overnight. Chiral HPLC indicated approximately 90% D3-ARI-143 was consumed, yielding two isomers (S:R = 8:2). The mixture was carefully quenched by the addition of acetone (200 mL) and then concentrated to remove the organic solvent. The residue was dissolved in acetone (2 L) and vinyl acetate (500 mL) and Novozym 435 (100.0 g, 10000 u / g) were added. The resulting suspension was stirred at 40 °C for 48 h.
[0195] The mixture was filtered to recover Novozym 435 (recycled), and the filtrate was concentrated. The residue was triturated with EtOAc / EtOH to give D3-ARI-164 (1.1 g, 50% yield, ee 98.2% by chiral HPLC, deuteration ratio 99% by NMR) as a yellow solid, and the mother liquor was further purified by silica gel column chromatography (DCM / EtOAc / THF = 3:1:1) to give another batch of D3-ARI-164 (15.7 g, 10% yield. Two batches gave 80.2 g as 53% yield) and compound Ac-D3-ARI-164 (16.3 g, 10% yield). 1H-NMR (400 MHz, DMSO-d6): δ 12.24-12.25 (d, J = 2.0 Hz, 1H), 9.10-9.12 (d, J = 3.2 Hz, 1H), 8.27-8.32 (dd, J = 5.6 and 8.4 Hz, 1H), 7.37-7.41 (dd, J = 2.4 and 9.6 Hz, 1H), 7.11-7.17 (m, 1H), 5.47 (bs, 1H), 4.73 (s, 1H), 0.91-0.93 (d, J = 6.8 Hz, 3H); LC-MS: m / z 306.0 [M−H] - .
[0196] Example 26: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (ARI-186) [ka] Step 1: Preparation of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide [ka] In a 20 mL microwave vessel, thiazole-4-carbaldehyde (1.27 g, 11.23 mmol) was combined with (S)-2-methylpropane-2-sulfinamide (1.36 g, 11.23 mmol), followed by the addition of titanium isopropoxide (6.65 mL, 22.45 mmol). The vessel was heated to 70 °C in a microwave reactor for 15 min. Upon completion, the suspension had completely dissolved. The cooled reaction mixture and a parallel reaction mixture (previously derived from 18.83 mmol of aldehyde 1) were added to a rapidly stirring solution of 300 mL of EtOAc and 5 mL of saturated NaCl. A fine white ppt was obtained, which was removed by filtration through a Celite pad. TLC (EtOAc / heptane) indicated the reaction was complete. The mixture was adsorbed onto Celite and then concentrated to dryness. Chromatography (40 g silica gel, heptane to 80% EtOAc / heptane) afforded an off-white solid. The solid was co-evaporated twice with CHCl and heptane, then placed under high vacuum to afford (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide (5.46 g, 25.2 mmol, 84% yield) as an off-white solid. 1 H NMR (500 MHz, CDCl3) δ 8.93 (d, J = 2.0 Hz, 1H), 8.74 (s, 1H), 8.02 (d, J = 2.0 Hz, 1H), 1.29 (s, 9 H); ESI MS m / z 217 [M+H] + .
[0197] Step 2: Preparation of (S)-2-methyl-N-(1-(thiazol-4-yl)propyl)propane-2-sulfinamide [ka] To a −78° C. solution of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide (511 mg, 2.36 mmol) in THF (24 mL) was added dropwise ethylmagnesium bromide (1.0 M in THF) (2.60 mL, 2.60 mmol). The solution remained clear and colorless upon addition. The reaction was allowed to warm slowly to room temperature overnight. In the morning, saturated NH4Cl was added. HPLC showed a ratio of 5.69:1. A trace of product was also formed, which was identified as the reduction product (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide. The reaction was quenched by the addition of saturated NH4Cl followed by EtOAc. The aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. Chromatography (24 g silica gel, heptane to EtOAc, dry loaded silica gel) afforded the desired product (493 mg, 85%). 1 It was obtained as a mixture of diastereomers by H NMR (5.8:1 diastereomeric ratio) and as a white solid after coevaporation with CHCl / heptane. A portion of this mixture was evaluated for crystallization. To the solid sulfinamide (304 mg) was added dichloromethane (2 mL), and upon dissolution, heptane (8.00 mL) was added. The colorless solution was stirred at room temperature under N while slowly draining the DCM with a blood needle. A solid began to form at the edge. The mixture was sonicated briefly to afford a significant solid. After 1 hr, the solid was isolated by filtration, yielding 53.9 mg after drying in vacuo. 1 Only 1% traces of the diastereomers were estimated by H NMR. A second crop of crystals from the concentrated filtrate was isolated using a slower crystallization process. Excess CH2Cl2 (10 mL) was combined with heptane (25 mL). This was allowed to slowly concentrate by evaporation overnight. The resulting solid was isolated as white needles (83.4 mg). 1 Only 1% traces of diastereomers were estimated by H NMR, which was combined with batch 1 to give an overall yield of 45%. Main diastereomers: 1H NMR (500 MHz, CDCl3) δ 8.78 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 4.43 (app q, J = 7.0 Hz, 1H), 3.87 (d, J = 7.2 Hz, 1H), 1.98 (m, 2H), 1.24 (s, 9H), 0.90 (t, J = 7.4 Hz, 3H); ESI MS m / z 247 [M+H] + ; HPLC = 4.74 min, C18 Kinetex. Minor diastereomers (only the distinct signals provide reference): 1 H NMR (500 MHz, CDCl3) δ 8.79 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 4.54 (m, 1H), 3.64 (m, 1H), 1.18 (s, 9H). HPLC = 4.47min, C18 Kinetex.
[0198] Step 3: Preparation of (S)—N-((S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl)-2-methylpropane-2-sulfinamide [ka] To a −78° C. solution of (S)-2-methyl-N-(1-(thiazol-4-yl)propyl)propane-2-sulfinamide (59.5 mg, 0.241 mmol) in 500 μL of THF was added n-butyllithium (1.6 M in hexanes) (0.309 mL, 0.495 mmol) via a gastight syringe. The solution remained clear for the first equivalent of BuLi. Upon addition of the second equivalent, the solution turned pale yellow. The reaction mixture was warmed to −40° C. over 40 min. This solution was added dropwise via cannula to a −15° C. solution of tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (89 mg, 0.276 mmol) in THF (0.5 mL). The dianion vessel was rinsed with 500 μL of THF and transferred via cannula to a Weinreb vessel. Upon addition of the dianion, the solution turned emerald green. After approximately 15 min, the green color faded to a dull olive green. After an additional 20 min, the reaction was quenched with saturated NH4Cl and stirred. 0.5 mL of 3N HCl was then added to ensure complete decomposition of the Weinreb intermediate. The working solution eventually turned from olive green to yellow / orange. The mixture was extracted with EtOAc, dried over Na2SO4, filtered, and concentrated to give crude (S)-N-((S)-1-(2-(6-fluoro-1H-indole-3-carbonyl)thiazol-4-yl)propyl)-2-methylpropane-2-sulfinamide (estimated 0.241 mmol). LCMS indicated the desired Boc product (ESI MS m / z 508 [M+H] + ) and the des-Boc product (ESI MS m / z 408 [M+H] + ) are shown. The product was used without further purification.
[0199] Step 4: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone [ka] To crude tert-butyl 3-(4-(1-(((S)-tert-butylsulfinyl)amino)propyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (122 mg, 0.241 mmol) was added MeOH (10 ml), followed by HCl (4 M in dioxane) (1 ml, 4.00 mmol). LCMS indicates predominantly sulfinamide deprotection. The reaction was concentrated to dryness. The residue was treated with MeOH and 1 mL of 2N NaOH was added. The residue was absorbed onto Celite with MeOH and then concentrated to dryness. Reverse-phase chromatography (30 g C18, 10% HO / CH3CN + 0.1% NH4OH to 50% CH3CN, dry loading) gave a clean separation, affording (4-(1-aminopropyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (48.2 mg, 66%) as a yellow solid after lyophilization. LCMS showed both desired Boc products (ESI MS m / z 304 [M+H] + ). Major diastereomer retention time = 4.38 min (ARI-186), OJ-X, 4.6 x 150 mm, 5 micron, 25% MeOH + 0.05% DEA / CO2 isocratic, 2.2 mL / min, column temperature: 35 °C, 254 nM uv and mass detection. Minor diastereomer = 4.13 min (ARI-187).
[0200] Example 27: Preparation of (S)-(4-(1-aminoethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (ARI-232) [ka] Step 1: Preparation of (S)-2-methyl-N-((S)-1-(thiazol-4-yl)ethyl)propane-2-sulfinamide [ka] To a −78° C. solution of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide (506 mg, 2.339 mmol) in CHCl (20 mL) was added dropwise methylmagnesium bromide (3.0 M in EtO) (0.858 mL, 2.57 mmol). The solution gradually turned yellow upon addition, with no appreciable exotherm. The reaction was allowed to warm slowly to room temperature overnight. The reaction was quenched by the addition of saturated NHCl. The aqueous layer was extracted with CHCl. The combined organic layers were washed with brine, dried (NaSO), filtered, and concentrated. 1 H NMR indicates an 8:1 ratio of diastereomers. Stereochemistry is tentatively assigned assuming Grignard behaves similarly to EtMgBr. Chromatography (24 g silica gel, heptane to EtOAc, dry loaded silica gel) produced a poorly defined elution profile. Fractions were combined. The solid (466 mg, 8:1 diastereomeric ratio) was dissolved using CHCl (15 mL), followed by the addition of 50 mL of heptane. Continued stirring resulted in crystallization. Needles (396.5 mg, 73% yield) were isolated by filtration. 1 H NMR estimates the presence of 3.8% traces of diastereomers. The solid (396.5 mg) was dissolved in minimal CHCl (approximately 2 mL), then 8 mL of heptane was added. The mixture was stirred. Crystals formed within 5 min. The mixture was sonicated briefly to reduce the crystal size, then the vessel was capped and stirred overnight. Fine white needles were isolated by filtration to give (S)-2-methyl-N-((S)-1-(thiazol-4-yl)ethyl)propane-2-sulfinamide (318 mg, 58.5% overall yield). 1 H NMR estimated the presence of <1% of a minor diastereomer. Main diastereomers: 1H NMR (500 MHz, DMSO-d6) δ 9.04 (d, J = 2.0 Hz, 1H), 7.55 (dd, J = 0.9, 2.0 Hz, 1H), 5.61 (d, J = 7.5 Hz, 1H), 4.53 (app pentet, J = 6.9 Hz, 1H), 1.48 (d, J = 6.8 Hz, 3H), 1.12 (s, 9H); ESI MS m / z 233 [M + H] + , HPLC = 4.09 min, C18 Kinetex; Minor diastereomers (only a selection of clearly separated signals provides reference): 1 H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 0.8, 2.0 Hz, 1H), 5.44 (d, J = 6.6 Hz, 1H); HPLC = 3.78 min, C18 Kinetex.
[0201] Step 2: Preparation of tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate [ka] To a suspension of (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide (156 mg, 0.671 mmol) in 1.5 mL of THF at −78 °C, n-butyllithium (1.6 M in hexanes) (0.860 mL, 1.376 mmol) was added via syringe. The suspension turned pale pink and dissolved fully after warming to −50 °C. This solution was added dropwise via cannula to a −35 °C solution of tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (238 mg, 0.738 mmol) in THF (0.5 mL). The dianion vessel was rinsed with 500 μL of THF and transferred via cannula to a Weinreb vessel. Upon addition of the dianion, the solution turned olive green and then emerald green. After approximately 20 min, the green color turned dark olive green (now at -15 °C). After an additional 20 min, the reaction was quenched with saturated NH4Cl and stirred. Subsequently, 0.5 mL of 3N HCl was added to ensure complete decomposition of the Weinreb intermediate. The working solution eventually turned from olive green to yellow / orange. The mixture was extracted with EtOAc, dried over Na2SO4, filtered, and concentrated to give crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (0.671 mmol). LCMS indicated the desired product (ESI MS m / z 494 [M+H] + ) and the des-Boc product (ESI MS m / z 394 [M+H] + ) are shown. The product was used without further purification.
[0202] Step 3: (S)-(4-(1-aminoethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone [ka] To crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (0.671 mmol) was added MeOH (10 ml) followed by HCl (4 M in dioxane) (1 ml, 4.00 mmol). LCMS indicates predominantly sulfinamide deprotection. The reaction was concentrated to dryness. The residue was treated with MeOH (10 mL) and 1 mL of 2N NaOH was added. Upon completion, the residue was absorbed onto Celite with MeOH and then concentrated to dryness. Reverse-phase chromatography (100 g C18, 10% HO / CH3CN + 0.1% NH4OH to 50% CH3CN, dry load) followed by normal-phase chromatography (24 g silica gel, CHCl2 to 18:2:80 MeOH:NH4OH:CHCl2, dry load) afforded (S)-(4-(1-aminoethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (151 mg, 78%) as a yellow solid after lyophilization. 1 H NMR (500 MHz, DMSO-d6) δ 9.13 (s, 1H), 8.28 (dd, J = 8.7, 5.6 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.37 (dd, J = 9.6, 2.3 Hz, 1H), 7.15 - 7.10 (m, 1H), 4.22 - 4.18 (m, 1H), 1.43 (d, J = 6.7 Hz, 3H); 19 F NMR (470 MHz, DMSO-d6) δ -118.87; ESI MS m / z 288 [M - H] -
[0203] Example 28: Preparation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-(methylamino)ethyl)thiazol-2-yl)methanone (ARI-233) [ka] Step 1: Preparation of tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)(methyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate [ka] To a −78°C suspension of (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide (144 mg, 0.620 mmol) in 2 mL of THF was added n-butyllithium (1.6 M in hexanes) (0.794 mL, 1.27 mmol) via syringe. The yellow solution was slowly warmed to −40°C over 40 min. The dianion was added dropwise via cannula to a −15°C solution of tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (220 mg, 0.682 mmol) in THF (0.5 mL). The dianion vessel was rinsed with 500 μL of THF and transferred via cannula to a Weinreb vessel. Upon addition of the dianion, the solution turned olive and then emerald green. After approximately 15 min, the green color turned dark olive green. After an additional 20 min, iodomethane (0.039 mL, 0.620 mmol) was added at 0 °C. The reaction was allowed to warm to room temperature overnight and then quenched by the addition of saturated NH₄Cl. The mixture was stirred. Subsequently, 0.5 mL of 3N HCl was added to ensure complete decomposition of the Weinreb intermediate. The working solution eventually turned from olive green to yellow / orange. The mixture was extracted with EtOAc, dried over Na₂SO₄, filtered, and concentrated to give crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)(methyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (0.620 mmol). LCMS indicated the desired Boc product (ESI MS m / z 508 [M+H] + ) and the des-Boc product (ESI MS m / z 408 [M+H] + ) are shown. The product was used without further purification.
[0204] Step 2: Preparation of (S)-(6-fluoro-1H-indol-3-yl)(4-(1-(methylamino)ethyl)thiazol-2-yl)methanone [ka] To crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)(methyl)amino)ethyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (0.621 mmol) was added MeOH (10 ml), followed by HCl (4 M in dioxane) (2 ml, 8.00 mmol). LCMS showed primarily sulfinamide deprotection. The reaction was concentrated to dryness. The residue was treated with MeOH (10 mL) and 2 mL of 2 N NaOH was added. Upon completion (<1 hr), the residue was adsorbed onto silica gel with MeOH and then concentrated to dryness. Chromatography (40 g silica gel, CHCl to 18:2:80 MeOH:NHOH:CHCl, dry loading) afforded (S)-(6-fluoro-1H-indol-3-yl)(4-(1-(methylamino)ethyl)thiazol-2-yl)methanone (68.4 mg, 36%) as a yellow solid after lyophilization from acetonitrile and water. 1 H NMR (500 MHz, DMSO-d6) δ 12.20 (s, 1H), 9.12 (s, 1H), 8.29 (dd, J = 8.7, 5.6 Hz, 1H), 7.81 (s, 1H), 7.37 (dd, J = 9.6, 2.3 Hz, 1H), 7.15 - 7.11 (m, 1H), 3.88 (q, J = 6.6 Hz, 1H), 2.25 (s, 3H), 1.40 (d, J = 6.7 Hz, 3H); 19 F NMR (470 MHz, DMSO-d6) δ -118.86; ESI MS m / z 302 [M−H] - .
[0205] Example 29: Preparation of (4-(aminomethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (ARI-234) [ka] Step 1: Preparation of (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide [ka] To a solution of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide (361 mg, 1.669 mmol) in MeOH (20 mL) was added sodium borohydride (126 mg, 3.34 mmol). After 1 h, water (5 mL) was added and combined with crude material from a parallel reaction using 0.328 mmol of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide. After stirring for 1 h, the reaction was concentrated to dryness and then adsorbed onto silica gel with MeOH and concentrated to dryness. Chromatography (24 g silica gel, CHCl to 80:18:2 CHCl:MeOH:NHOH, dry loading) afforded (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide (415 mg, 95%) as a white solid after coevaporation with CHCl / heptane. 1 H NMR (500 MHz, CDCl3) δ 8.79 (d, J = 2.0 Hz, 1H), 7.30 (m, 1H), 4.51 (ABq, J = 3.1, 14.6 Hz, 2H), 3.74 (bs, 1H), 1.24 (s, 9H); ESI MS m / z 219 [M + H] + .
[0206] Step 2: Preparation of tert-butyl (S)-3-(4-(((tert-butylsulfinyl)amino)methyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate [ka] To a −78°C solution of (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide (415 mg, 1.901 mmol) in 5 mL of THF was added n-butyllithium (1.6 M in hexanes) (2.435 mL, 3.90 mmol) via syringe. The solution turned pale pink and then yellow. After warming to −40°C over 40 min, this solution was added dropwise via cannula to a −15°C solution of tert-butyl 6-fluoro-3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (674 mg, 2.091 mmol) in THF (3 mL). The dianion vessel was rinsed with 2 mL of THF and transferred via cannula to a Weinreb vessel. Upon addition of the dianion, the solution turned olive green. After approximately 15 min, the reaction turned orange-brown. The reaction was allowed to warm to 5 °C over 1 h, and then the reaction was quenched with saturated NH4Cl. Subsequently, 1 mL of 3N HCl was added to ensure complete decomposition of the Weinreb intermediate. The mixture was extracted with EtOAc, dried over Na2SO4, filtered, and concentrated to give crude tert-butyl (S)-3-(4-(((tert-butylsulfinyl)amino)methyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (1.901 mmol). LCMS indicated the desired Boc product (ESI MS m / z 480 [M+H] + ) and the des-Boc product (ESI MS m / z 380 [M+H] + ) are shown. The product was used without further purification.
[0207] Step 3: (4-(aminomethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone [ka] To the crude tert-butyl (S)-3-(4-(((tert-butylsulfinyl)amino)methyl)thiazole-2-carbonyl)-6-fluoro-1H-indole-1-carboxylate (1.901 mmol) was added MeOH (10 ml), followed by HCl (4 M in dioxane) (2 ml, 8.00 mmol). LCMS indicates primarily sulfinamide deprotection. Upon completion (<1 hr), the reaction was concentrated to dryness. The residue was treated with MeOH (15 mL) and 4 mL of 2 N NaOH was added. Upon completion (<1 hr), the residue was adsorbed onto silica gel with MeOH and then concentrated to dryness. Chromatography (40 g silica gel, CHCl to 18:2:80 MeOH:NHOH:CHCl, dry loading) afforded a yellow solid. The solid was taken up in hot MeOH and then treated with activated charcoal. Filtration gave (4-(aminomethyl)thiazol-2-yl)(6-fluoro-1H-indol-3-yl)methanone (404 mg, 77%) as a yellow solid after lyophilization from acetonitrile and water. 1 H NMR (500 MHz, DMSO-d6) δ 9.14 (s, 1H), 8.29 (dd, J = 8.7, 5.6 Hz, 1H), 7.81 (m, 1H), 7.36 (dd, J = 9.6, 2.3 Hz, 1H), 7.15 - 7.10 (m, 1H), 3.95 (d, J = 0.9 Hz, 2H); 19 F NMR (470 MHz, DMSO-d6) δ -118.89; ESI MS m / z 276 [M+H] + .
[0208] Example 30: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-indol-3-yl)methanone (ARI-235) [ka] Step 1: Preparation of (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide [ka] A mixture of methylmagnesium bromide (3 M in diethyl ether) (1.200 ml, 3.60 mmol) and diethylzinc (15 wt % in toluene) (1.079 ml, 1.200 mmol) was stirred at room temperature for 10 min and then cooled to −78°C. A solution of (S,E)-2-methyl-N-(thiazol-4-ylmethylene)propane-2-sulfinamide (519 mg, 2.399 mmol) in THF (15 ml) was then added dropwise slowly over 40 min and stirred at −78°C for an additional 20 min. Saturated NH4Cl was added and the bath was removed. EtOAc was added and the layers were separated. The aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated to give 581 mg of a white solid, which consisted of a 5.8:1 ratio of the desired (S,S) to (S:R) product and only 1.7% of the reduced imine (i.e., (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide). The crude solid was dissolved by boiling heptane (50 mL). The heat was removed and the mixture was stirred. A white solid subsequently appeared. The mixture was sonicated briefly, and the solid was collected by filtration to give 430 mg. 1 H NMR shows predominantly the (S,S) diastereomer plus 1.9% of the (S,R) diastereomer and a trace of (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide. A second crystallization was performed by treating the white solid (430 mg) with boiling heptane (10 mL). The hot solution was cooled to ambient temperature. The resulting solid was briefly sonicated and then isolated by vacuum filtration to give (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide (399 mg, 67% yield) as a white solid. 1 H NMR shows <1% of the (S,R) diastereomer. 1H NMR (500 MHz, CDCl3) δ 8.78 (d, J = 2.0 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 4.43 (app q, J = 7.0 Hz, 1H), 3.87 (d, J = 7.2 Hz, 1H), 1.98 (m, 2H), 1.24 (s, 9H), 0.90 (t, J = 7.4 Hz, 3H); ESI MS m / z 247 [M+H] + .
[0209] Step 2: Preparation of tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)propyl)thiazole-2-carbonyl)-1H-indole-1-carboxylate [ka] To a −78°C suspension of (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide (658 mg, 2.67 mmol) in 8 mL of THF was added n-butyllithium (1.6 M in hexanes) (3.42 mL, 5.48 mmol) via syringe. The suspension became a yellow solution and was warmed to −40°C over 40 min. After this solution was added dropwise via cannula to a −15°C solution of tert-butyl 3-(methoxy(methyl)carbamoyl)-1H-indole-1-carboxylate (895 mg, 2.94 mmol) in THF (3 mL). The dianion vessel was rinsed with 2 mL of THF and transferred via cannula to a Weinreb vessel. Upon addition of the dianion, the solution turned green. After approximately 15 min, the reaction turned orange-brown. After allowing the reaction to warm to 5°C over 1 hour, the reaction was quenched with saturated NH4Cl. Subsequently, 1 mL of 3N HCl was added to ensure complete decomposition of the Weinreb intermediate. The mixture was extracted with EtOAc, dried over Na2SO4, filtered, and concentrated to give crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)propyl)thiazole-2-carbonyl)-1H-indole-1-carboxylate (2.67 mmol). LCMS indicated the desired Boc product (ESI MS m / z 490 [M+H] + ) and the des-Boc product (ESI MS m / z 388 [M−H] - ) are shown. The product was used without further purification.
[0210] Step 3: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-indol-3-yl)methanone [ka] To the crude tert-butyl 3-(4-((S)-1-(((S)-tert-butylsulfinyl)amino)propyl)thiazole-2-carbonyl)-1H-indole-1-carboxylate (2.67 mmol) was added MeOH (15 ml) followed by HCl (4 M in dioxane) (3 ml, 12.00 mmol). LCMS indicates primarily sulfinamide deprotection. Upon completion (<1 hr), the reaction was concentrated to dryness. The residue was treated with MeOH (15 mL) and 4 mL of 2 N NaOH was added. Upon completion, the residue was treated with 3 N HCl until neutral. The solvent was concentrated to dryness. The crude material was then adsorbed onto silica gel using MeOH and then concentrated to dryness. Chromatography (40 g silica gel, CHCl to 18:2:80 MeOH:NHOH:CHCl, dry loading) afforded a yellow solid of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-indol-3-yl)methanone after lyophilization from acetonitrile and water. 1 H NMR (500 MHz, DMSO-d6) δ 12.18 (bs, 1H), 9.12 (s, 1H), 8.32 - 8.30 (m, 1H), 7.80 (d, J = 0.6 Hz, 1H), 7.57- 7.55 (m, 1H), 7.29 - 7.24 (m, 2H), 3.98 (app t, J = 6.5 Hz, 1H), 2.20 (bs, 2H), 1.90 - 1.82 (m, 1H), 1.75 - 1.66 (m, 1H), 0.90 (t, J = 7.3 Hz, 3H); ESI MS m / z 284 [M−H] - .
[0211] Example 31 Preparation of (S)—N-((2-(1H-indole-3-carbonyl)thiazol-4-yl)methyl)-2-methylpropane-2-sulfinamide (ARI-236) [ka] Step 1: Preparation of (S)—N-((2-(1H-indole-3-carbonyl)thiazol-4-yl)methyl)-2-methylpropane-2-sulfinamide [ka] To a suspension of (S)-2-methyl-N-(thiazol-4-ylmethyl)propane-2-sulfinamide (298 mg, 1.365 mmol) in THF (3900 μL) at −78° C. was added n-butyllithium (1.6 M in hexanes) (1749 μL, 2.80 mmol). The suspension became a pale yellow solution and was warmed to −40° C. over 40 min. Separately, N-methoxy-N-methyl-1H-indole-3-carboxamide (307 mg, 1.501 mmol) in THF (4 mL) was treated with sodium hydride (85 mg, 2.125 mmol) at room temperature to give a thick suspension of a gray solid. This mixture was cooled to −40° C., and then the dianion previously prepared above was added via cannula. The reaction mixture was allowed to warm to room temperature overnight with stirring. The resulting tan solution was treated with saturated NH4Cl. EtOAc and 3N HCl (1 mL) were added and the layers were separated. The organics were washed with brine, dried (NaSO), filtered, and concentrated to a solid (1.365 mmol; ESI MS m / z 362 [M + H] + The crude product was collected as is.
[0212] Step 2: Preparation of (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone [ka] To the crude (S)—N-((2-(1H-indole-3-carbonyl)thiazol-4-yl)methyl)-2-methylpropane-2-sulfinamide (1.365 mmol) was added MeOH (15 ml), followed by HCl (4 M in dioxane, 3 ml, 12.00 mmol). Upon completion (<1 hr), the reaction was concentrated to dryness. The residue was treated with MeOH (15 mL) and saturated NaHCO3 was added until neutral. The solvent was concentrated to dryness. The crude material was then adsorbed onto silica gel with MeOH and then concentrated to dryness. Chromatography (25 g silica gel, CHCl to 18:2:80 MeOH:NHOH:CHCl, dry loading) afforded (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone (231 mg, 65% yield) as a yellow solid after lyophilization from acetonitrile and water. 1 H NMR (500 MHz, DMSO-d6) δ 12.20 (bs, 1H), 9.14 (s, 1H), 8.32 - 8.30 (m, 1H), 7.80 (s, 1H), 7.57- 7.55 (m, 1H), 7.29 - 7.24 (m, 2H), 3.94 (app d, J = 0.9 Hz, 2H), 2.07 (bs, 2H); ESI MS m / z 258 [M + H] + .
[0213] Example 32: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone can be synthesized from (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0214] Example 33 Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone can be synthesized from (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0215] Example 34: Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[3,2-c]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[3,2-c]pyridin-3-yl)methanone can be synthesized from (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0216] Example 35 Preparation of (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[3,2-b]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminopropyl)thiazol-2-yl)(1H-pyrrolo[3,2-b]pyridin-3-yl)methanone can be synthesized from (S)-2-methyl-N-((S)-1-(thiazol-4-yl)propyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0217] Example 36: Preparation of (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone can be prepared from (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0218] Example 37 Preparation of (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone can be prepared from (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0219] Example 38 Preparation of (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[3,2-c]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[3,2-c]pyridin-3-yl)methanone can be prepared from (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[3,2-c]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0220] Example 39 Preparation of (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[3,2-b]pyridin-3-yl)methanone [ka] (S)-(4-(1-aminoethyl)thiazol-2-yl)(1H-pyrrolo[3,2-b]pyridin-3-yl)methanone can be prepared from (S)-2-methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide and N-methoxy-N-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide according to the method described in Example 31, except that N-methoxy-N-methyl-1H-indole-3-carboxamide is used instead of N-methoxy-N-methyl-1H-indole-3-carboxamide.
[0221] Example 40 Preparation of (4-((S)-1-(methylamino)ethyl)thiazol-2-yl)(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone [ka] (S)-2-Methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide is dissolved in dry THF cooled to -20°C, and an equivalent amount of sodium hydride is added thereto. The solution is stirred for 10 min, and then 1.2 equivalents of methyl iodide is added thereto. The solution is stirred for 2 hours, then evaporated to dryness, and then redissolved in dry THF, and the solution is filtered under a nitrogen atmosphere. The THF solution is then cooled to -78°C, and 1.1 equivalents of n-BuLi is added thereto. The solution is then warmed to -40°C. This solution is added via cannula to a preformed solution of the sodium salt of N-methoxy-N-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (prepared by adding 1 equivalent of sodium hydride to a THF solution of (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone) in THF maintained at −15°. After warming to room temperature overnight, the solution is mixed as described in Example 31.
[0222] Example 41 Preparation of (4-((S)-1-(methylamino)ethyl)thiazol-2-yl)(1H-pyrrolo[2,3-c]pyridin-3-yl)methanone [ka] (S)-2-Methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide is dissolved in dry THF cooled to -20°C, and 1 equivalent of sodium hydride is added to it. The solution is stirred for 10 min, and then 1.2 equivalents of methyl iodide are added to it. The solution is stirred for 2 hours, and then evaporated to dryness, and then redissolved in dry THF, and the solution is filtered under a nitrogen atmosphere. The THF solution is then cooled to -78°C, and 1.1 equivalents of n-BuLi are added to it. The solution is then warmed to -40°C. This solution is added via cannula to a preformed solution of the sodium salt of N-methoxy-N-methyl-1H-pyrrolo[2,3-c]pyridine-3-carboxamide (prepared by adding 1 equivalent of sodium hydride to a THF solution of (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone) in THF kept at −15° C. After warming to room temperature overnight, the solution is mixed as described in Example 31.
[0223] Example 42: Preparation of (4-((S)-1-(methylamino)ethyl)thiazol-2-yl)(1H-pyrrolo[3,2-c]pyridin-3-yl)methanone [ka] (S)-2-Methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide is dissolved in dry THF cooled to -20°C, and 1 equivalent of sodium hydride is added to it. The solution is stirred for 10 min, and then 1.2 equivalents of methyl iodide is added to it. The solution is stirred for 2 hours, and then evaporated to dryness, and then redissolved in dry THF, and the solution is filtered under a nitrogen atmosphere. The THF solution is then cooled to -78°C, and 1.1 equivalents of n-BuLi is added to it. The solution is then warmed to -40°C. This solution is added via cannula to a preformed solution of the sodium salt of N-methoxy-N-methyl-1H-pyrrolo[3.2-c]pyridine-3-carboxamide (prepared by adding 1 equivalent of sodium hydride to a THF solution of (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone) in THF maintained at −15° C. After warming to room temperature overnight, the solution is mixed as described in Example 31.
[0224] Example 43 Preparation of (4-((S)-1-(methylamino)ethyl)thiazol-2-yl)(1H-pyrrolo[3,2-b]pyridin-3-yl)methanone [ka] (S)-2-Methyl-N-(1-(thiazol-4-yl)ethyl)propane-2-sulfinamide is dissolved in dry THF cooled to -20°C, and 1 equivalent of sodium hydride is added to the solution. The solution is stirred for 10 min, and then 1.2 equivalents of methyl iodide are added to the solution. The solution is stirred for 2 hours, then evaporated to dryness, and then redissolved in dry THF, and the solution is filtered under a nitrogen atmosphere. The THF solution is then cooled to -78°C, and 1.1 equivalents of n-BuLi are added to the solution. The solution is then warmed to -40°C. This solution is added via cannula to a preformed solution of the sodium salt of N-methoxy-N-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide in THF (prepared by adding 1 equivalent of sodium hydride to a THF solution of (4-(aminomethyl)thiazol-2-yl)(1H-indol-3-yl)methanone) maintained at -15°C. After warming to room temperature overnight, the solution is mixed as described in Example 31.
[0225] Example 44: Stimulation of CYP1A1 in human HepG2 cells CYP1A1 induction is under the control of the AhR signaling pathway. This example describes an in vitro assay (7-ethoxy-resorufin-O-deethylase (EROD) assay) that evaluated the AhR-modulating activity of the indole compounds described herein. In this assay, the indole compounds were incubated with human HepG2 cells or mouse Hepa1-6 cells. The activity of CYP1A1 in the cells was measured by the conversion of the substrate 7-ethoxyresorufin, whose readout is a fluorescent signal associated with the conversion product. The EC of the indole compounds in the assay 50 The value and the maximum luminescence induced thereby were determined.
[0226] material Human HepG2 cells were obtained from Sigma Aldrich (Catalog 85011430-1VL).
[0227] method Human HepG2 cells were grown to 60-80% confluence in tissue culture flasks, detached with a non-enzymatic cell dissociation solution (cell stripper), seeded at 5,000 cells per well into 384-well plates, treated with test compounds, and incubated at 37°C for 20 hours or overnight. The reaction was initiated by removing the treatment medium and adding a solution of the substrate 7-ethoxyresorufin (ETX). The plate was incubated at 37°C for 30 minutes. The reaction was then terminated by the addition of tempered methanol. Fluorescence emission was measured at 590 nm with excitation at 530 nm in a FLEXSTATION III instrument (Molecular Devices).
[0228] result Table 2 shows the EROD assay data for ARI-001 (ITE), ARI-143, ARI-145, ARI-146, ARI-164, ARI-186, ARI-187, ARI-194, ARI-195, ARI-210, ARI-211, ARI-212, ARI-213, ARI-214, ARI-215, ARI-218, ARI-219, ARI-220, ARI-221, ARI-222, ARI-223, ARI-224, ARI-225, ARI-226, ARI-228, and ARI-229 derivatives using human HepG2 cells. [Table 2]
[0229] The results from the above table show that several chiral alcohols and chiral amines showed potency and chiral preference, especially in human HepG2 cells: ARI-186 is more EC-efficient than ARI-187 50 9.5x stronger at EC 90 was 20.5x stronger; ARI-186 is more EC-efficient than ARI-164 50 17.8x more powerful than EC 90 was 18.0x stronger; ARI-224 is more EC-efficient than ARI-164 50 3.1x more powerful and EC 90 was 0.90x more potent; and ARI-226 is more EC-efficient than ARI-164 50 It is 4.2x more powerful than EC 90 It was 4.2x more powerful.
[0230] Surprisingly, chiral selection for S vs. R was maintained in some instances. For example, ARI-186 exhibited a higher EC than ARI-187. 50 9.6x more powerful than EC 90 Similarly, ARI-218 was 20.6x more potent than ARI-219 at EC 50 19.7x stronger than EC 90 It was 53x more powerful.
[0231] Example 45: Determination of metabolic stability of indole compounds The liver is an important organ in the body for drug metabolism. This example describes a hepatocyte-specific clearance assay using both human and rat hepatocytes to evaluate the metabolic stability of the indole compounds disclosed herein. The measured parameters are t 1 / 2 (half-life), CL int (intrinsic clearance) and E H (liver extraction ratio).
[0232] material Testosterone (Lot FE111011-01) was obtained from Cerilliant (Round Rock, TX). 7-Hydroxycoumarin (Lot 11631ED) was obtained from Sigma-Aldrich (St. Louis, MO). Cryopreserved human hepatocytes pooled from 10 male donors (X008001), cryopreserved male IRC / CD-1 mouse hepatocytes (M005052), INVITROGRO HI medium (incubation), and INVITROGRO HT medium (thawing) were obtained from Bioreclamation IVT (Baltimore, MD). All solvents were obtained from commercial sources and used without further purification.
[0233] method Metabolic stability in hepatocytes Each test compound was prepared as a 1 mM stock solution in DMSO. 2 μM solutions of the test compounds and positive controls were prepared in INVITROGRO HI medium (incubation). These solutions were prewarmed in a sterile incubator set to maintain 37°C, 5% CO2, and 98% humidity. Cryopreserved hepatocytes were cultured at 2 x 10 in incubation medium. 6 The compound solution and hepatocyte mixture were then combined in a 1:1 (v:v) ratio. The final volume of the reaction mixture was 750 μl, containing 1 μM test compound (10 μM for 7-hydroxycoumarin) and 1 x 10 6The reaction mixture was placed in an incubator on a plate shaker. After 0, 15, 30, 60, 90, and 120 minutes of incubation, 100 μl of the reaction mixture was removed from the incubation plate and mixed with 150 μl of ice-cold acetonitrile in the designated wells of a 96-well crash plate. The 96-well crash plate was placed on ice for 15 minutes, and the samples were centrifuged (3,600 RPM, 10 minutes, 4°C) to precipitate proteins. The supernatant was diluted 1:1 (v:v) with water containing 0.15 μM verapamil and / or 1 μM tolbutamide (internal standards for positive and negative modes, respectively) in a 96-well shallow-bottom injection plate. The plate was sealed for LC-MS analysis. All measurements were performed in duplicate.
[0234] LC-MS analysis Liquid chromatography Column: Waters Atlantis T3 column, 100Å, 3μm, 2.1mm x 50mm (Part#186003717). Mobile phase A: Water with 0.1% formic acid. Mobile phase B: Acetonitrile with 0.1% formic acid. Flow rate: 0.7mL / min. Gradient program: [Table 3] Total run time: 3 min. Autosampler: 10 μl injection volume. Autosampler wash: A: 90% water, 10% acetonitrile; B: 90% acetonitrile, 10% water.
[0235] mass spectrometer Instrument: AB SCIEX API4000. Interface: Turbo Ionspray. Mode: Q1 Multiple Ions. Method: 3.0 min duration. Mass spectrometer source settings: [Table 4]
[0236] Data and Calculations t at 60 minutes 1 / 2 , C.L. int , EH and %R determination The remaining compound (%R) was determined from the LC-MS peak area by comparison to time point 0. Metabolic half-life (t 1 / 2 ) and intrinsic clearance (CL int ) values were calculated from the slope of the plot of ln(%R) versus time and the concentration of hepatocytes present during the incubation. Percent survival at 60 minutes was calculated by incorporating the 60 minute value into the equation for the slope generated by the percent survival time point.
[0237] Calculation of in vivo liver clearance In vivo liver clearance CL H is the following formula:
number
[0238] Liver Extraction Ratio E H is the following formula:
number
[0239] result Table 4 shows the t values of various indole compounds described herein when assayed on human and rat hepatocytes. 1 / 2 , C.L. int and E H Shows. [Table 6-1] [Table 6-2]
[0240] These results indicate that ARI-186 is effective in rats at 4.1 μl / min / 10 6 Cell CL int and 21.6% liver extraction ratio. This Clint value is 1.8x lower than that of ARI-164. In humans, AR-186 also exhibited a Clint value of 1.5 μl / min / 10 6 Cell CL int and had a low clearance with a liver extraction ratio of 8.7%. int The value was 10.8x lower than that of ARI-164. ARI-224 and ARI-226 had slightly lower values than ARI-164 in rats. However, in human cells, both compounds showed significantly higher CL activity compared to ARI-164. int had at least a 4x improvement in
[0241] Example 46: CYP profiling of indole compounds To examine the contribution of CYP1A2 and CYP3A4 to the metabolism of compounds of the present disclosure, human liver microsomes were incubated with test compounds for 30 minutes in the presence of the selective chemical inhibitors furafylline (1A2) and ketoconazole (3A4).
[0242] result: Table 5 shows the turnover rates of the test compounds. [Table 7]
[0243] Confirming previous studies, ARI-164 was shown to have a 30-minute metabolic turnover, with 37% metabolism. In the presence of furafylline, only 4% of ARI-164 was metabolized, demonstrating 89% inhibition by the CYP1A2 inhibitor. However, in the presence of ketoconazole, there was only an 8% inhibitory effect. Thus, ARI-164 is selectively metabolized by CYP1A2.
[0244] ARI-186 was shown to be a very low turnover compound, with only 13% metabolized in 30 minutes. Importantly, neither furafylline nor ketoconazole had a significant effect on ARI-186 metabolism.
[0245] ARI-224 and ARI-226 similarly had low turnover with little to no effect on metabolism in the presence of furafylline or ketoconazole.
[0246] Thus, ARI-186, ARI-224 and ARI-226 are compounds that appear to selectively eliminate the CYP1A1 / 1A2-mediated oxidation of ARI-164 while preserving or improving efficacy.
[0247] Surprisingly, some chiral pairs appear to exhibit distinct differences in metabolic turnover and CYP metabolic liability. For example, ARI-223 has a high metabolic turnover with a CYP1A2 metabolic contribution, whereas ARI-224 does not. Similarly, ARI-225 has a high metabolic turnover with a CYP1A2 metabolic contribution, whereas ARI-226 does not. Also, ARI-228 has a high metabolic turnover with a CYP1A2 metabolic contribution, whereas ARI-229 does not.
[0248] Example 47: In vivo pharmacokinetic studies in mice and rats This example describes a pharmacokinetic (PK) study of ARI-164, ARI-165, ARI-186, ARI-224, and ARI-226 in mice and rats. In this study, test compounds were administered intravenously (IV) at 2 mg / kg or orally (PO) at 10, 30, or 40 mg / kg to groups of mice and / or rats (N=3 in each group). ARI-186, ARI-224, and ARI-226 were administered orally to rats at 10 mg / kg QD for 5 days to assess whether their reduced susceptibility to CYP1A1 / 1A2 metabolism leads to increased accumulation. IV doses were prepared in DMSO, and PO doses were prepared in a 50 / 50 mixture of PEG400 and Tween 80 (single-dose mouse and rat studies for ARI-164, ARI-165, ARI-186, ARI-224, and ARI-226) or PEG400 / Kolliphor HS15 / oleic acid 45 / 45 / 10 (ARI-164 repeat-dose rat study). Blood samples were collected pre-dose and over 24 hours post-dose. Plasma concentrations of test compounds were determined by HPLC.
[0249] result: Tables 6a-h below show the results of PK studies for selected compounds in rats and mice. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5] [Table 8-6] [Table 8-7] [Table 8-8]
[0250] Surprisingly, this study showed that after a single 40 mg / kg oral dose of ARI-186, the AUC was 73,900 ng*hr / ml with 75.7% oral bioavailability (Table 6f). This is a major improvement over a single 40 mg / kg oral dose of ARI-164, which achieved only 3,008 ng*hr / ml with 15.1% oral bioavailability (Table 6e). This is a 24.6x improvement in AUC and a 5.0x improvement in oral bioavailability. The half-life for ARI-186 was in the range of 7.6 hours, significantly longer than the ARI-164 half-life in mice of 1.4 hours.
[0251] Surprisingly, ARI-164 showed a greater than 90% reduction in exposure after repeated oral dosing in rats at 30 mg / kg QD, while ARI-186 saw a 4.9x accumulation from 5,940 ng*hr / ml on day 1 to 29,100 ng*hr / ml on day 5, thereby confirming the in vitro results with ARI-186 and suggesting that ARI-186 had achieved steady-state pharmacokinetics after five doses.
[0252] Furthermore, ARI-186 showed accumulation toward steady state after 5 days of repeated dosing, whereas, surprisingly, ARI-224 and ARI-226 did not (Tables 6g and 6h). Indeed, ARI-224 and ARI-226 showed increased elimination after induction of CYP1A1 / 1A2. This suggests that although each of these compounds has the same 6-fluoroindole moiety and the same chiral amino group, structural variations on the thiazole terminus of the molecule contribute significantly to the CYP metabolic profile of these molecules.
[0253] Example 48: Antitumor activity of ARI-143, ARI-164, and ARI-165 in animal models This example describes an in vivo study evaluating the anticancer efficacy of ARI-143, ARI-164, ARI-165, and ARI-186 in a syngeneic mouse tumor model. Mice subcutaneously implanted with EMT-6 or Pan02 cancer cells were treated with ARI-143, ARI-164, ARI-165, ARI-186, or a vehicle control, as described below.
[0254] material and method cell culture Monolayer cultures of tumor cells were maintained in vitro in DMEM or RPMI1640 medium supplemented with 10% fetal bovine serum at 37°C in a 5% CO atmosphere. Cells in the exponential growth phase were harvested and quantified using a cell counter before tumor inoculation. The cell lines used are listed in the table below. [Table 9]
[0255] Subcutaneous syngeneic mouse tumor model Two subcutaneous syngeneic mouse tumor models were generated by inoculating female BALB / C or C57BL / 6 mice with cancer cells into the right lower or right anterior flank, as detailed in the table below: [Table 10]
[0256] Each mouse was subcutaneously inoculated with tumor cells in 0.1 mL of PBS. The average tumor size was approximately 80–120 mm. 3 (approx. 100mm 3 Treatment was initiated when the tumor cell inoculation time reached 0 days. The administration of test compounds and the number of animals in each test group are shown in the study design. The day of tumor cell inoculation was marked as day 0.
[0257] Formulation of test compounds ARI-143, ARI-164, and ARI-165 were dissolved in DMSO at a final concentration of 26.7 mg / ml and stored at room temperature. In the Pan02 study of ARI-164 and ARI-186, both compounds were dissolved in 100% PEG400.
[0258] Test Design The average tumor size is approximately 90 mm 3 Randomization of animals was initiated to form mouse test groups when the serotonin concentration reached 1.000. TM Randomization was performed using a randomized block design based on the "matched distribution" method (software, version 3.1.399.19). Groups of mice (10 per group) were treated with vehicle (DMSO or PEG400) or test compounds at doses of 20-80 mg / kg by intraperitoneal (ip) injection QD over 28 days.
[0259] Observation and data collection After tumor cell inoculation, mice were examined daily for morbidity and mortality. During routine monitoring, mice were examined for tumor growth and any effects of treatment on behavior, such as mobility, food and water consumption, weight gain / loss (body weight was measured twice a week after randomization), eye / hair matting, and any other abnormalities. Mortality and observed clinical signs were recorded in detail for each individual mouse.
[0260] Measure tumor volume twice a week in two dimensions using calipers and calculate by the formula: V=(LxWxW) / 2 where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L) to calculate the volume in mm 3 Dosing and tumor and body weight measurements were performed in a laminar flow cabinet. Body weight and tumor volume were recorded using StudyDirectory. TM Measurements were performed using software (version 3.1.399.19).
[0261] Day off administration After a single measurement of >30% body weight loss (BWL), mice were given a dosing rest day, the length of which was long enough to allow weight recovery to <30% BWL, at which point treatment was resumed. During the dosing rest day, mice were not given any further nutritional support.
[0262] End of experiment The tumor growth inhibition percentage (TGI %) is an indicator of the antitumor activity of a drug compound: TGI(%)=100x(1-T / C) where T and C are the mean tumor volumes (or weights) of the treatment and control groups, respectively, on a given day. Statistical analysis of the differences in mean tumor volumes (MTV) between groups was performed using data collected on the day the MTV of the vehicle group reached its humane endpoint, so that TGI could be obtained for all or most of the mice enrolled in the study.
[0263] The weight of all animals was monitored throughout the study and animals were euthanized if they lost more than 20% of their starting weight and failed to recover within 72 hours.
[0264] All mice in the same group had an MTV of 2000 mm 3 Mice were sacrificed when they reached a tumor volume of 3000 mm or individual mice were sacrificed when their tumor volume reached 3000 mm. 3 They are slaughtered when they reach this age.
[0265] To discourage cannibalism, any animals that displayed ulcerated or necrotic tumors were immediately separated, single-housed, and monitored daily before euthanasia or until tumor regression was complete. Mice with tumor ulceration of approximately 25% or more of the tumor surface were euthanized.
[0266] statistical analysis Comparisons between two groups were performed using the Student's t-test. All data were analyzed using SPSS 18.0 and / or GraphPad Prism 5.0. P<0.05 was considered statistically significant.
[0267] result To evaluate the antitumor activity of ARI-143, ARI-164, ARI-165, and ARI-186, in vivo studies were performed in the syngeneic mouse tumor models described above. [Table 11] [Table 12] [Table 13]
[0268] Surprisingly, ARI-186 was significantly more effective at suppressing Pan02 tumors at 20 mpk than ARI-164 at 80 mpk: On study day 18, 20 mpk of ARI-186 produced 62% tumor inhibition relative to vehicle, compared with 80 mpk of ARI-164, which produced 35% tumor inhibition relative to vehicle (FIG. 20C).
[0269] Example 49: In vivo antitumor activity of ARI-164 in combination with anti-PD-1 antibodies In this example, the in vivo anti-tumor efficacy of the combination of ARI-164 and an anti-PD-1 antibody was evaluated using a panel of seven subcutaneous syngeneic mouse tumor models.
[0270] material and method Subcutaneous syngeneic mouse tumor model Seven subcutaneous syngeneic mouse tumor models were generated by inoculating female BALB / C or C57BL / 6 mice with cancer cells into the right lower or right front flank and then randomizing them, as detailed in Table 10 below. [Table 14] Formulation of anti-PD-1 antibody, ARI-164 Rat monoclonal anti-mouse PD-1 antibody (isotype IgG) at a concentration of 6.61 mg / ml 2aA solution of κ) was obtained from BioXcell (in vivo MAb anti-mouse PD-1 (CD279), clone RMP1-14, Cat#BE0146) and stored at 4°C. The antibody solution was diluted with PBS to obtain a 1 mg / ml dosing solution.
[0271] ARI-164 powder was stored at −20° C. Compound powders were dissolved in DMSO to give respective dosing solutions of 26.7 mg / ml for administration to mice at 40 mg / kg.
[0272] Study design and randomization Seven studies were conducted using seven subcutaneous syngeneic mouse tumor models. In each study, 80 mice were enrolled and randomly assigned to eight different study groups with 10 mice per study group. The average tumor size at randomization was approximately 80-120 mm. 3 (approx. 100mm 3 ) was the "matched distribution" randomization method (StudyDirector TM Randomization was performed based on the software (version 3.1.399.19). Table 6 shows the study design and the actual dosing frequency and number. All drugs and vehicle controls were injected intraperitoneally into mice. [Table 15-1] [Table 15-2]
[0273] Data were collected and analyzed as described above in Example 48.
[0274] result Tumor growth inhibition 21A-G are graphs showing the mean tumor volumes on different study days in the study groups indicated according to each of studies 1-7. TGI data are summarized in Table 12. [Table 16]
[0275] 4T-1 is a highly aggressive breast cancer line resistant to anti-PD-1. Surprisingly, ARI-164 not only slowed tumor growth, thereby improving survival, but its combination with anti-PD-1 antibody resulted in a statistically significant delta in tumor growth inhibition at day 31 of the study (Figure 21A).
[0276] The combination of ARI-164 and anti-PD-1 antibody resulted in significant tumor inhibition in the A20 model at study day 28 (Figure 21B).
[0277] The combination of ARI-164 and anti-PD-1 antibody resulted in significant tumor inhibition in the EMT-6 model at day 30 of the study (Figure 21C).
[0278] The combination of ARI-164 and anti-PD-1 antibody resulted in increased tumor inhibition in Pan02 at study day 55, but given that Pan02 is almost completely insensitive to anti-PD-1, most of this activity could be due to ARI-164 (Figure 21D).
[0279] The combination of ARI-164 and anti-PD-1 antibody resulted in significant tumor inhibition in the H22 model at study day 24 (Figure 21E).
[0280] The combination of ARI-164 and anti-PD-1 antibody resulted in tumor inhibition on study day 32, with most of this activity likely due to ARI-164 (Figure 21F).
[0281] The combination of ARI-164 and anti-PD-1 antibody resulted in significant tumor inhibition in the MC38 model at day 27 of the study (Figure 21G). The present invention includes the following aspects. Item 1 Structural formula 2: [ka] or a pharmaceutically acceptable salt thereof (In the formula: X 1 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X 2 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X 3 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon); X 4 is N (nitrogen), O (oxygen), S (sulfur), or C (carbon), and X 1 、X 2 、X 3 and X 4 At least one of is N and X 1 、X 2 、X 3 and X 4 are optionally selected to form a heteroaromatic group, where X 1 and between adjacent carbons, X 2 and between adjacent carbons, X 1 and X 4 During X 2 and X 3 Between and X 3 and X 4 The bond between X may be a single bond or a double bond; 1 、X 2 、X 3 and X 4 The valence of is H or C 1 -C 6 alkyl (i.e., the ring can be aromatic, partially saturated, or saturated); Z 1 is N or CR 4 and Z 2 is N or CR 5 and Z 3 is N or CR 6 and Z 4 is N or CR 7 and Z 5 is N or CR 8 and Z 6 is N or C, and Z 7 is N or C, where Z 1 、Z 2 、Z 3 、Z 4 、Z 5 、Z 6 and Z 7 Two or fewer of are N; R 2 is OR O , N(R N ) 2 or SR S and; R O is H, CN, substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, or carbonylamino, where the alkyl, alkenyl, alkynyl, or alkanoyl is optionally interrupted by O, S, or NR (where NR can be N-C1-C6 alkyl), or a phosphate moiety; R S is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; Each R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety; R 3a is selected from the group consisting of hydrogen, deuterium, cyano, or C1-C6 alkyl; R 3 is deuterium, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, C 1 -C 6 Acyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 10 (n=0-2, R 10 is directly attached to S), where R 10 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R 4 、R 5 、R 6 、R 7 、R 8 and R 9 are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 11 (n=0-2, R 11 is directly attached to S), where R 11 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; R 1 and R 1a Let's get together =NR b where R b is H, C 1 -C 6 Alkyl, hydroxy, C 1 -C 6 Alkoxy (-O-alkyl), C 1 -C 6 Acyloxy, amino or C 1 -C 6 Acyl and R 2 may preferably be ═O, and R 3 is preferably -OR, where R is H or C 1 -C 6 is alkyl, or R 1 and R 1a Let's get together, =CR b R c where R b and R c are independently H, C 1 -C 6 alkyl, alkoxy (-O-alkyl), thioalkoxy (-S-alkyl), cyano (-CN), or amino; R 2 may preferably be ═O, and R 3 is preferably -OR, where R is H or C 1 -C 6 is alkyl, or R1 and R 1a Together =O, =NOR a Or form =S and R 2 and R 3 are preferably each independently -OR or -NR a R b where R and R a and R b are independently H, C 1 -C 6 Alkyl or C 1 -C 6 is acyl, or R 1 and R 1a are each independently hydrogen, deuterium, halo, amino, hydroxy, cyano, formyl, furyl, nitro, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, halothiocarbonylthio, and -S(O) n R 12 (n=0-2, R 12 is directly attached to S), where R 12 is selected from the group consisting of hydrogen, deuterium, halo, amino, hydroxy, thiol, cyano, formyl, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, acyloxy, alkoxy, haloalkoxy, thioalkoxy, halothioalkoxy, alkanoyl, haloalkanoyl, thioalkanoyl, halothioalkanoyl, carboxy, carbonyloxy, halocarbonyloxy, carbonylthio, halocarbonylthio, thiocarbonyloxy, halothiocarbonyloxy, thiocarbonylthio, and halothiocarbonylthio; The compound is R 2 / R 3 / R 3a and optionally adjacent R groups can be joined to form a 3- to 12-membered ring). Section 2 Structural formula 2a;
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
change
Claims
1. Structural formula 8a or Structural formula 8b 【Chemistry 1】 (In the formula, R 4 , R 5 , R 6 and R 7 are each independently selected from the group consisting of hydrogen and halo; R o is hydrogen, deuterium, alkyl, aryl or acyl; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety. or a pharma- ceutically acceptable salt thereof.
2. Structural formula 8c or Structural formula 8d 【Chemistry 2】 (In the formula, R 4 , R 5 , R 6 and R 7 are each independently selected from the group consisting of hydrogen and halo; R o is hydrogen, deuterium, alkyl, aryl or acyl; R N is H, CN, alkyl, alkenyl, alkynyl, aryl, alkanoyl, carbonyloxy, carbonylthio, carbonylamino, or a phosphate moiety. or a pharma- ceutically acceptable salt thereof.
3. R o The compound of claim 1 or 2, wherein is H, alkyl or acyl.
4. R o is substituted or unsubstituted C 1 -C 6 Acyl, substituted or unsubstituted C 1 -C 6 Acyl is a substituted C optionally interrupted by O, S or NR, where NR can be N-C1-C6 alkyl. 2 , C 3 , C 4 , C 5 or C 6 3. The compound of claim 1 or 2, which may be acyl, wherein the substituent is a halo, carboxyl, amino, hydroxyl, alkoxy or phosphonate moiety.
5. R 4 , R 5 , R 6 and R 7 At least one of is F, Cl or Br, and R 4 , R 5 , R 6 and R 7 The compound according to any one of claims 1 to 4, wherein the other of is hydrogen.
6. R 5 is F or Cl, and R 4 , R 6 and R 7 The compound according to any one of claims 1 to 4, wherein is hydrogen.
7. R 6 is F or Cl, and R 4 , R 5 and R 7 The compound according to any one of claims 1 to 4, wherein is hydrogen.
8. R 7 is F or Cl, and R 4 , R 5 and R 6 The compound according to any one of claims 1 to 4, wherein is hydrogen.
9. R 5 and R 6 is F or Cl, and R 4 and R 7 The compound according to any one of claims 1 to 4, wherein is hydrogen.
10. R 5 and R 7 is F or Cl, and R 4 and R 6 The compound according to any one of claims 1 to 4, wherein is hydrogen.
11. R 6 and R 7 is F or Cl, and R 4 and R 5 The compound according to any one of claims 1 to 4, wherein is hydrogen.
12. R 4 , R 5 , R 6 and R 7 The compound according to any one of claims 1 to 4, wherein each of is hydrogen.
13. structure 【Chemistry 3】 or 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof.
14. structure 【Chemistry 5】 or 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 and a pharma- ceutically acceptable carrier.
16. 16. The pharmaceutical composition of claim 15 for stimulating or modulating the immune system in a patient in need thereof.
17. 17. The pharmaceutical composition of claim 16, wherein the compound reduces IL-21 levels in the patient.
18. 18. The pharmaceutical composition of claim 16 or 17, wherein the patient has cancer.
19. 16. The pharmaceutical composition of claim 15 for treating cancer in a patient in need thereof.
20. 20. The pharmaceutical composition of claim 19, wherein the cancer is selected from the group consisting of lymphoma, leukemia, myeloma, prostate cancer, lung cancer, ovarian cancer, cervical cancer, breast cancer, skin cancer, colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, renal cancer, bladder cancer, soft tissue cancer, glioma and head and neck cancer.
21. 21. The pharmaceutical composition of claim 19 or 20, wherein said treatment further comprises administering to the patient another cancer therapeutic agent.
Citation Information
Patent Citations
Preparation and use of ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
JP2004527482A
Synthesis of indole thiazole compounds as ligands for ah receptors
JP2005525340A
ITE for the Intervention and Eradication of Cancer
JP2013509411A
Indole compounds as aryl hydrocarbon receptor (AHR) modulators
JP2021503498A
Methods of treating cancer
WO2020106695A1
